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A BRIEF ELEVATION OF SERUM AMYLOID A IS SUFFICIENT TO 
INCREASE ATHEROSCLEROSIS 
 
Cardiovascular disease is now the leading cause of death worldwide.  Serum 
amyloid A (SAA), a positive acute phase reactant, along with C-reactive protein is 
used clinically as a marker of cardiovascular disease risk.  However, recent data 
has shed light on a possible causal role of SAA in the development of 
atherosclerosis, the most pervasive form of cardiovascular disease.  Several 
inflammatory diseases such as diabetes and obesity are known to confer 
increased risk of developing cardiovascular disease.  Individuals with these 
diseases all have modest but persistent elevation of SAA.  To determine if SAA 
caused the development of atherosclerosis, apoe-/-  chow fed mice were injected 
with either an adenoviral vector expressing human SAA1 (ad-hSAA1), a null 
adenoviral vector (ad-Null) or saline.  Human SAA levels rapidly increased, albeit 
briefly then returned to baseline within 14 days in mice that received ad-hSAA1.  
After 16 weeks, mice that received ad-hSAA1 had significantly increased 
atherosclerosis compared to controls on the aortic intimal surface (p<0.0001), 
aortic sinus (p<0.05) and the brachiocephalic artery (p<0.05).   According to the 
“response to retention” hypothesis; lipoprotein retention by vascular wall 
proteoglycans is a key initiating event in the development of atherosclerosis.  We 
previously reported that SAA-stimulated vascular smooth muscle cells expressed 
biglycan with increased glycosaminoglycan chain length and increased binding 
affinity for low density lipoprotein.  To further test the role of biglycan on the 
development of atherosclerosis we generated biglycan transgenic mice.  These 
mice were crossed to the ldlr-/- mouse on a C57BL/6 background and fed a pro-
atherogenic western diet for 12 weeks.  There was a significant increase in 
atherosclerotic lesion area on the aortic intimal surface (p<0.05) and the aortic 
sinus (p<0.006), as well as a significant correlation between vascular biglycan 
content and aortic sinus atherosclerotic lesion area (p<0.0001).  These data 
demonstrate that transiently increased SAA resulted in increased atherosclerosis 
compared to control mice, possibly via increased vascular biglycan content.  In 
support of this we found that biglycan transgenic mice had significantly increased 
atherosclerosis compared to wildtype controls, likely through increased lipid 
retention in the vascular wall. 
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Chapter 1: Introduction  
1.1 Initiation of atherosclerosis:  competing hypotheses 
 
 The Response to injury 1.1.1
 
  The single initiating event in the development of atherosclerosis has yet to 
be defined.  Over the years many theories have been tested providing a great 
deal of information regarding the origins of atherosclerotic plaques in the 
vasculature.  One of the pioneers in the study of early atherosclerosis was Dr. 
Russell Ross. He championed the “response to injury” hypothesis of 
atherosclerosis which proposed that some insult to the endothelium represented 
the key initiating event in atherosclerosis. He argued that endothelial dysfunction 
caused by mechanical stress, homocysteine exposure, oxidized LDL, toxins as 
well as other triggers was sufficient to establish the beginnings of fatty streak 
formation, the first histologically visible manifestation of atherosclerosis.  The 
body of his work focused on the activation of inflammatory signaling cascades in 
response to these endothelial insults (1).  However, morphological analysis of 
lesion development revealed several concepts that contradict the theories of 
Ross et al.  First, most lesions maintain an intact endothelial layer until they 
become very advanced, rupture-prone atheromas (2).  Second, endothelial 
denudation, which is a known side effect of balloon angioplasty, does not result 
in plaque formation (3).  Another major component of the “response to injury” 
1 
 
theory related to endothelial cells is the expression of vascular adhesion 
molecules. Vascular cell adhesion molecule 1 (VCAM1) and intercellular 
adhesion molecule 1 (ICAM1) are both expressed on the luminal surface of 
endothelial cells in response to injury or inflammatory stimuli within the vessel 
wall.  While this response is certainly necessary for the overall homeostasis of 
the vessel as it recruits leukocytes to points of injury, it can also be very 
problematic.  If the stimuli driving adhesion molecule expression is itself 
dysregulated, the signaling of inflammatory cells will lead to excess leukocyte 
recruitment and inflammation; and the potential for disease development as seen 
in the progression of atherosclerosis. Inflammatory cytokines such as TNF-α and 
IL-1 are capable of stimulating the expression of adhesion molecules in 
endothelial cells; however, some signal must be present to drive the expression 
and secretion of these cytokines (4).  The identification of the underlying driving 
force for inflammatory cytokine secretion is one area where the “response to 
injury” hypothesis remains incomplete.  The “response to injury”  also presents 
ox-LDL as a molecule capable of causing endothelial dysfunction (5).  The 
limitation of this idea is that the plasma environment inhibits most oxidation of 
lipoproteins (6).   Moreover, any amount  of oxidized LDL found in circulation is 
cleared very rapidly by the liver (7), thus it’s not likely to interact with the vessel 
wall in appreciable amounts.   It’s been demonstrated that LDL and other 
lipoproteins naturally flux in and out of the vessel wall (8), suggesting that 
lipoprotein flux is not pathogenic; however, the retention of those lipoproteins 
might be.   All of the above mentioned processes, endothelial dysfunction, 
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adhesion molecule expression and the presence of ox-LDL are very important in 
the progression of atherosclerosis; however, the evidence simply does not 
support the idea that any of them are individually sufficient to initiate the 
development of atherosclerosis.  
 
 The Response to Retention 1.1.2
 
  The gaps in explaining the development of atherosclerosis through 
vascular injury lead to the “response to retention” hypothesis of early 
atherosclerosis.  It surmises that the retention of lipoproteins in the 
subendothelial space by vascular proteoglycans is an initiating event in the 
development of atherosclerosis (9).  Much of the early evidence for retention as 
an initiating event in atherosclerosis was done in rabbit models.  When made 
rapidly hypercholesterolemic via bolus injection of LDL, arterial lipid content 
increased within minutes to hours.  Importantly, it was shown that the rate limiting 
step in lipid accumulation in the vessel wall was a lack of egress, meaning the 
LDL particles were being retained by some component of the subendothelial 
compartment (10).  The molecules most implicated in the retention of LDL in the 
vessel wall are proteoglycans, which have negatively charged 
glycosaminoglycan side chains capable of interacting with positively charged 
motifs on apolipoprotein B (11).  Evidence for this interaction has been 
demonstrated both histologically and biochemically. 
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The importance of this lipoprotein/proteoglycan interaction on the 
development of atherosclerosis was demonstrated by a series of experiments 
using mice transgenic for several mutations of apolipoprotein B.  The mutations 
involved amino acid substitutions of several sites on the apolipoprotein B 
molecule identified as important in either LDL receptor binding or proteoglycan 
binding (11).  In mice with apolipoprotein B lacking the ability to bind to 
proteoglycans, the degree of atherosclerosis was significantly less than those 
mice with normal proteoglycan binding, independent of the cholesterol levels.  
This implied that elevated total cholesterol was not sufficient to cause severe 
early atherosclerosis independent of proteoglycan binding (12).  However, follow-
up work related to proteoglycan binding defective apolipoprotein B demonstrated 
that, given enough time, the degree of atherosclerotic lesion development in all 
groups ultimately reached the same magnitude.  Furthermore, lipoprotein lipase 
was identified to play a key role in bridging lipoproteins to proteoglycans in 
middle to late developing lesions; events that take place well after lipid retention 
has been established (13).  Thus, lipoprotein/proteoglycan interaction is 
important for the initiation of atherosclerosis; however, it may not be required as 
other mechanisms such as molecules capable of bridging lipoproteins to 
proteoglycans have been identified (13). 
 Evidence that  lipoprotein retention precedes 1.1.3
inflammation  
 
Franks et al demonstrated lipoprotein retention prior to histologically 
relevant lesion formation utilizing freeze-etch electron microscopy.  Lipid droplets 
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in the subendothelial space of hyperlipidimic apoe-/- aortas, but not C57BL/6 
control aortas,  were clearly evident as early as three weeks of age (14)..  Franks 
work was greatly extended by Nakashima et al, who investigated the progression 
of early atherosclerosis in human coronary arteries. They established a scoring 
system, with a scale of 0-3, based on the degree of lipid deposition in the 
subendothelial space of the arteries.  Lesions scoring zero presented with only 
diffuse intimal thickening, a physical change in the vessel wall marked by 
increased matrix deposition.   No lipid deposition was observed in lesions scored 
with zero.  Conversely, lesions with a score of three had extensive lipid retention 
with accompanying macrophage infiltration.  Their data demonstrated that lipid 
retention was only identified after diffuse intimal thickening, implying that matrix 
deposition was a key initiating event in the development of atherosclerosis.  
Once lipid retention progressed to some critical level, macrophages began to 
infiltrate the vessel wall, appearing to translocate exclusively from the luminal 
side of the vessel (15).  Thus, their chronology of early atherosclerosis was:  
increased matrix deposition followed by lipid retention then followed by 
macrophage infiltration (16).    The evidence clearly pointed to atherosclerosis as 
a disease of retention followed by inflammation.   
 
1.2 Biglycan  
 
 Biglycan regulation 1.2.1
 
5 
 
With regards to the “Response to Retention” hypothesis, the proteoglycan 
most associated with lipid retention in both human and murine atherosclerotic 
lesions is the small leucine rich proteoglycan biglycan (17).  The gene for this 
small proteoglycan is located on the X chromosome, where it encodes a highly 
conserved core protein with a mass of about 42 kDa (18).  Biglycan possesses 
two glycosaminoglycan side chains composed of chondroitin or dermatan sulfate 
disaccharide repeats (19), attached to the N-terminus of the core protein (20).  
The promoter region of the biglycan gene possesses AP2 sites, IL-6 response 
elements, an NF-κB site and a TGF-beta negative element.  Actual regulation of 
the biglycan gene varies greatly depending on the cell type and developmental 
stage (21).  For instance, in chondrocytes retinoic acid down regulates biglycan; 
however, in skeletal muscle retinoic acid had no effect on biglycan but did 
increase expression of the closely related proteoglycan decorin (22).  It has also 
been clearly demonstrated that TGF-beta increases biglycan in most cell types 
(23) including glomerular mesangial cells (24).  In osteoblastic cells, IGF-1 and 
IGF-2, both known to stimulate bone development have also been shown to 
increase biglycan expression (25).        
 
 Biglycan and the extracellular matrix 1.2.2
 
Within the vasculature, biglycan is expressed in many different cell types. 
However, the predominant site of synthesis is the vascular smooth muscle cells, 
where it is secreted as part of the extracellular matrix.  When initially 
characterized some 30 years ago, biglycan’s normal physiological function within 
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the matrix, particularly bone, was thought to be interacting  with and stabilizing 
matrix components such as collagen (26) and elastin fibers (27).  Thus, biglycan 
was assumed to play an integral, albeit inert, role within the extracellular 
compartment.  The importance of biglycan in stabilizing the extracellular matrix 
was demonstrated recently in biglycan deficient mice.   These mice had an 
increased incidence of spontaneous aortic dissection and rupture due primarily to 
weakly organized collagen fibrils which resulted in aortas with low tensile 
strength (28).  The rate of aortic dissection and rupture in biglycan deficient mice 
was further exacerbated by infusion of angiotensin II (29).  Biglycan’s residence 
in the extracellular matrix underscores many of its important, recently identified 
biological functions.  Many studies now suggest that biglycan  is a regulator of 
growth factors and inflammatory cytokines such that it is now regarded as a 
member of the innate immune system (30).  Proteolytic enzymes such as bone 
morphogenic protein 1 (BMP1), matrix metalloproteinases (MMP) and granzyme 
B can cleave biglycan’s core protein releasing it from the extracellular matrix 
where it then acts as a “danger signal” ligand for many different receptors.  
Mitogen activated protein kinase p38 (MAPK), extracellular signal-regulated 
kinase (ERK) and nuclear factor kappa-light chain enhance of activated B cells 
(NF-κB) are rapidly phosphorylated when soluble biglycan binds to Toll like 
receptor 2 and 4.  Macrophages stimulated via biglycan/Toll like receptor 
interaction had a profoundly increased expression of macrophage inflammatory 
protein-1α (MIP-1α) and monocyte chemoattractant protein-1(MCP-1) resulting in 
the recruitment of more monocyte/macrophages to sites of tissue injury (31) (32).  
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Biglycan has also been shown to induce inflammation by clustering Toll like 
receptors with the receptor P2X7 to activate the NLRP3 inflammasome ultimately 
leading to the secretion of mature IL-1β (33).  Biglycan has certainly been 
established as a key mediator of tissue injury derived inflammation; however, 
recent reports also demonstrated that biglycan can activate the adaptive immune 
response in macrophages and dendritic cells.  Once bound to Toll like receptors, 
biglycan was able to upregulate CXCL13, a major B cell attractant and biomarker 
of autoimmune inflammatory diseases (32).    
 Biglycan in atherosclerosis  1.2.3
 
Biglycan is the molecule most often associated with retention of lipids in 
early atherosclerotic lesions in both humans and mice (17).   Biglycan is 
upregulated by several cytokines that have been implicated in the development 
of atherosclerosis including angiotensin II and TGF-β (34, 35).   Studies have 
demonstrated that biglycan is present in both human and murine atherosclerotic 
lesions.   Interestingly, in human coronary arteries, versican is the predominant 
proteoglycan. However, when human coronary atherosclerotic lesions were 
examined for lipoprotein and proteoglycan co-localization, biglycan was the 
proteoglycan most likely to co-localize with the lipoproteins apolipoprotein E and 
apolipoprotein B.  Versican was associated with regions of low lipoprotein 
content (36).   In both apoe-/- and ldlr-/- mouse models, biglycan was present at all 
stages of aortic sinus lesion development co-localized with apolipoprotein A-I and 
apolipoprotein B lipoproteins (37).  Interestingly, biglycan stimulated by cytokines 
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associated with atherosclerosis had longer, more negatively charged GAG 
chains (38).  Such a modification would allow for a very strong ionic interaction 
between biglycan and the positive amino acid moieties found on lipoproteins 
such as apolipoprotein B (11).  Thus, biglycan, possibly by way of retaining pro-
atherogenic lipoproteins, is likely to play a role in the development of 
atherosclerosis.  Interestingly, the evidence that biglycan is capable of activating 
the innate immune system; and the importance of inflammation in the 
development of atherosclerosis (39), likely provides a second possible means by 
which biglycan is atherogenic.  As previously stated, TGF-β is a potent initiator of 
biglycan synthesis such that TGF-β warrants further discussion.  
  
1.3 Transforming Growth Factor β  
 
 The TGF-β superfamily 1.3.1
 
TGF-β is a member of the eponymously named TGF-β superfamily of 
cytokines and growth hormones that play an immense role in all aspects of 
development and maintenance of most organisms.  The family is comprised of 
several TGF-β isoforms as well as bone morphogenic proteins, activins, and 
nodals (40).  These molecules play a role in processes such as cell proliferation 
and differentiation, which represent key elements of TGF-β’s embryonic 
developmental programming.  However, it is TGF-β’s role in synthesis of 
extracellular matrix and regulation of immune cells that link it profoundly to the 
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development of atherosclerosis (41).  There are three isoforms of TGF-β 
represented within this family, being TGF-β1, TGF-β2 and TGF-β3.  They are all 
products of different genes and share approximately 80% sequence homology 
(42).  To date, the vast majority of data collected on these isoforms pertains to 
TGF-β 1 function.  Given its capacity to affect so many aspects of cellular 
homeostasis, TGF-β’s expression and regulation are tightly controlled both within 
the cell and once secreted to the extracellular compartment.    The TGF-β protein 
is synthesized as a pro-protein.  The pro-protein segment of the molecule must 
be cleaved prior to TGF-β being exported; however, it remains ionically 
associated with TGF-β and the two molecules are secreted as a latent complex 
(43).  Once in the extracellular compartment TGF-β is sequestered to the 
extracellular matrix by several molecules including biglycan.  TGF-β remains 
inactive until it is proteolytically cleaved by one of several matrix proteases, 
including plasmin, integrins but most often thrombospondin 1 (44).  Once 
liberated from the matrix, TGF-β becomes a ligand for  the transforming growth 
factor β type two receptor (TβRII).  This TGF-β complex then interacts with one of 
several transforming growth factor β type I receptors to initiate downstream 
signaling within the cell.  Several members of the SMAD protein family are 
primarily responsible for canonical TGF-β signal transduction within the cell; 
however, other pathways have been identified.  SMAD 2 & 3 are TGF-β receptor 
specific effector molecules that become phosphorylated upon TGF-β ligand 
binding and receptor complex formation.  The phospho-SMAD2/3 then 
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complexes with SMAD4 ultimately acting as a nuclear transcription factor driving 
the expression of TGF-β target molecules (45).   
 
The investigation of TGF-β function is made quite difficult by the fact that 
when knocked out, mice do not live more than a few weeks as a result of 
profound inflammation within the major organs, thus genetically derived loss of 
function studies are nearly impossible to perform (46).  Furthermore, modulation 
of TGF-β in vivo involves the use of inhibitory antibodies and soluble receptors to 
inactivate the cytokine while in circulation.  This fails to address the paracrine 
and autocrine capacities of TGF-β within the compartment for which it was 
synthesized and secreted (47).   This is why TGF-β’s physiological functions are 
loosely characterized as requiring the right cell type, the right cytokine 
concentration and the right timing (48).   
  
 TGF-β  and atherosclerosis 1.3.2
 
TGF-β proteins are synthesized in many cells including most cells present 
in atherosclerotic lesions such as vascular smooth muscle cells, leukocytes and 
endothelial cells (48).  A simplistic description of TGF-β action, particularly 
related to atherosclerosis, is to categorize it as anti-inflammatory and pro-fibrotic.  
However, again TGF-β signaling is very spatially and temporally dependent.  
Under homeostatic conditions, TGF-β inhibits cell proliferation and helps to 
maintain healthy extracellular matrix as its actions act in opposition to matrix 
degrading proteins such as matrix metalloproteinases(MMP) (45).  TGF-β has 
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been shown to maintain vascular smooth muscle cells in a contractile state, thus 
preventing the cells from adopting a synthetic phenotype which would result in 
increased matrix deposition (49).  Increased matrix accumulation including the 
deposition of the proteoglycan biglycan have been shown to associate with the 
early development of atherosclerosis by increasing the retention of lipoproteins in 
the vessel wall, thus setting off the cascade of events leading to fatty streak 
formation and ultimately the development of atheromas (50).   Thus, maintaining 
homeostatic levels of TGF-β is key step in maintaining vascular wall integrity; 
however, many molecules with links to cardiovascular disease are capable of 
increasing TGF-β levels.  Diseases such as diabetes are known to stimulate 
increased TGF-β expression (51).  Interestingly, individuals with diabetes also 
have a greater risk of developing cardiovascular disease (52).  Beyond disease 
states, several cytokines such as angiotensin II have been shown to increase 
plasma TGF-β levels.  Ldlr-/- mice infused with angiotensin II for 28 days via alzet 
pump implantation had a rapid 3 fold increase in TGF-β levels by day three. 
These mice also had increased atherosclerosis compared to saline infused mice.   
When a subset of these mice was concurrently treated with angiotensin II and the 
TGF-β neutralizing antibody 1D11, the induction of TGF-β was prevented.  
Furthermore, the mice receiving TGF-β inhibition had less atherosclerosis 
quantified in the aortic sinus (53).  Thus, TGF-β appeared to directly stimulate the 
development of atherosclerosis.  
However a consensus on TGF-β’s role in atherosclerosis is as yet 
undetermined.  Work by Mallat et al, using a pan-TGF-β inhibitory antibody to 
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decrease circulating levels of TGF-β1, TGF-β2 and TGF-β3, resulted in 
increased plaque size in apoe-/- male mice.  They also reported a much more 
inflamed plaque with increased macrophage content and decreased collagen 
fibers (54).  Increased inflammation and a lack of fibrous continuity within a lesion 
represents the hallmark of an unstable, clinically significant atheroma (55).  
Conversely, Lutgens et al reported that TGF-β inhibition in apoe-/- male mice via 
injection of a soluble TGF-β receptor resulted in a dramatic change in lesion 
cellularity with an influx of inflammatory cells.  However, when lesions were 
analyzed for atherosclerosis, the group that received TGF-β inhibition had a 
striking decrease in lesion area (56).  In summary, three models of TGF-β 
inhibition and atherosclerosis were studied.  One suggested that TGF-β was anti-
atherogenic; two suggested that TGF-β was pro-atherogenic; however the two 
suggesting TGF-β is pro-atherogenic differed greatly in the resulting inflammatory 
effects of TGF-β inhibition. Obviously, there is still a great deal of work to be 
done to understand TGF-β’s role in atherosclerosis.   
1.4 Serum amyloid A 
 
 SAA background 1.4.1
 
Serum amyloid A (SAA) is a family of highly conserved apoproteins.   
They are expressed in almost every vertebrate animal studied to date, ranging 
from humans, goats, fox, to the arctic char, a salmon-like fish (57).  This implies a 
significant evolutionary importance for this family of proteins.  Humans have four 
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unique isoforms of SAA and mice have 5, each with some allelic variation.  The 
genes for the human SAA isoforms are located on chromosome 11p15.1 within 
150kb of each other (58).  The genes for murine SAA are also located within very 
close proximity to one another, spanning approximately 45kb on chromosome 7.  
This chromosome locus is considered to be syntenic to the chromosome locus of 
human SAA (59).  Murine and human SAA’s are categorized based on their 
responsiveness to inflammatory or infectious stimuli.  Mice and humans share 
two homologous acute phase isoforms of SAA; SAA1 and SAA 2 in humans and 
SAA1.1 and SAA 2.1 in mice, which are synthesized primarily in the liver (60).  
Though mice and humans have varying numbers of alleles of both of these 
genes, human SAA1 is considered homologous to murine SAA1.1 and human 
SAA2 is considered homologous to murine SAA2.1.  During an acute phase 
response (APR) these protein variants can increase in concentration up to 1000 
fold over baseline levels (61).  Though the exact role for this substantial increase 
is not fully appreciated, it is thought to play a major role in activating the immune 
system to respond to acute stimuli.   As an APR resolves there is an equally 
rapid resolution of the serum concentrations of the acute phase SAA’s.    Mice 
possess another less understood acute phase SAA, SAA3.   This particular 
isoform is only modestly homologous to murine SAA1.1 and 2.1, sharing 
approximately 60% of the other acute forms’ sequence (62).  This is considered 
an extrahepatic acute SAA, expressed in macrophage and adipose tissue that 
does not contribute to circulating levels of SAA (63).  Murine SAA3’s homologue 
in the human genome was considered a pseudogene possessing a single 
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nucleotide mutation that inserts a premature stop codon into the sequence.  This 
sequence disruption was thought to be sufficient to prevent the protein from 
being synthesized (64) ;however, studies have begun to identify human SAA3 by 
RT-PCR (65).  Whether human SAA3 actually produces a functional gene 
product has yet to be determined.   Both humans and mice have another  isoform 
of SAA that is considered constitutively active as its serum levels do not change 
in the presence of acute inflammatory or infectious stimuli.  These SAA’s have an 
additional eight peptides generating a monomeric SAA about 2kDa larger than 
the acute isoforms (66).  Though both humans and mice express these 
constitutive isoforms, their function remains unknown.     
 
SAA has been most broadly investigated as the circulating precursor to 
complex amyloid plaques that form in tissue throughout the body during 
amyloidosis (67).  Surprisingly though, little is known structurally about the SAA 
family of proteins.  It had previously been reported that SAAs likely existed in an 
alternating helix- β−sheet conformation based on predictive structural analysis 
(68).  However, recently, Jinghua et al have identified several structural 
components of human SAA that have helped to explain some the molecule’s 
functions.  First and foremost, they identified that the protein contains four alpha 
helices and no β-sheet motifs.  Also, the structure has some homology to 
apolipoprotein E which is an interesting discovery given that SAA and 
apolipoprotein E have some similar binding capacities involving the bridging of 
lipoproteins to proteoglycan rich matrix (69).  They also revealed that the two 
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regions of helix 1 and 3 in each monomer thought to be amyloidogenic are buried 
in the native conformation of human SAA1, thus implying that SAA does not 
naturally aggregate into amyloid plaques (70).  Though the vast majority of work 
with SAA is focused on amyloidosis, a very robust body of literature is being 
cultivated investigating SAA’s role in cardiovascular disease. 
 
 SAA and cardiovascular disease 1.4.2
 
Modestly elevated SAA is a characteristic of many inflammatory diseases 
such as diabetes and obesity (71) (72).  Individuals who suffer from such 
diseases have an increased risk of developing heart disease, particularly 
atherosclerosis, though the exact etiology remains unknown (73).  SAA and high 
sensitivity C-reactive protein (hs-CRP) have long been regarded as very useful 
markers of inflammation, and both are quite robustly associated with 
cardiovascular disease outcomes (74).   hs-CRP is more widely accepted as a 
better marker for overall cardiovascular risk (75);  however, SAA may be a better 
indicator of the extent of disease present as shown by data analyzed as part of 
the Women’s Ischemia Syndrome Evaluation (WISE) trial (74).  
Not until recently though has SAA’s potential causal role in atherosclerosis 
been investigated.  Though SAA’s exact native biological role in both humans 
and mice is not fully understood, several potential pathologic features of SAA as 
they relate to the development of atherosclerosis have been identified.  Lee at al 
demonstrated that human monocytes in culture responded to SAA stimulation 
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with a dose dependent increase in CCL2, a potent monocyte chemoattractant 
found in atherosclerotic lesions.  They extended this work to reveal that SAA 
acted through the receptor FPRL1 to activate NF-κB to drive the observed CCL2 
synthesis (76).  We too have demonstrated that SAA’s effects on biglycan 
synthesis in vascular smooth muscle cells was dependent upon interaction 
between SAA and the FPRL1 receptor as competitive inhibition of the receptor 
rendered the cells insensitive to exogenous SAA (38).  It is well known that 
recruitment of inflammatory cells, particularly macrophages, into developing 
lesions is a key step in the progression of atherosclerosis from a disease of lipid 
retention to a disease of inflammation.  Once in the lesion, macrophage uptake of 
modified lipid particles results in the formation of lipid laden foam cells (9).  Lee 
et al continued their work on SAA to demonstrate that not only could SAA 
increase the recruitment of macrophages to lesions via increased CCL2 
expression, it could also directly stimulate the transition from macrophage to 
foam cell via LOX1 receptor activation (77).  Work by others has revealed that 
not only can SAA recruit macrophages, but other leukocytes as well (78).    SAA 
is an apoprotein most commonly associated with HDL.  Furthermore during 
inflammation, SAA becomes the predominant protein associated with HDL 
particles (79).  One of the main athero-protective functions of HDL is to promote 
reverse cholesterol transport (RCT), which involves the trafficking of peripheral 
lipids to the liver for excretion either as bile or feces (80).  SAA was previously 
thought to reduce RCT though it may simply be SAA associated inflammation 
driving that effect (81), as a recent study utilizing a murine model in which both 
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SAA1.1 and SAA2.1 were knocked out revealed that the effect of inflammation 
on RCT was independent of SAA (82).  The previously mentioned events 
surrounding atherosclerosis are not regarded as initiating events, but reveal a 
role for SAA in progression of the disease.   
 
Beyond its physiological effects on cytokines and inflammatory cells, SAA 
has also been visualized via immunohistochemistry in atherosclerotic lesions co-
localized with lipoproteins such as apoA-I and apoB in two murine models of 
atherosclerosis (83).  Interestingly SAA was also shown to interact with a class of 
molecules of particular interest in our lab, proteoglycans, and in particular 
biglycan.  Studies have revealed that HDL’s rate of retention within 
atherosclerotic lesions via interaction with vascular biglycan is directly related to 
the amount of SAA found associated with the HDL particle (84).   
 
The question of SAA’s direct role in increasing atherosclerosis was first 
addressed by the work of Dong et al when they overexpressed SAA in apoe-/- 
mice via injection of a lentiviral vector encoding murine SAA1.1.  Their data 
revealed that increased SAA directly accelerated the progression of 
atherosclerosis independent of all other risk factors.  Thus SAA for the first time 
was shown to be directly causal in the development of atherosclerosis.  Their 
mechanistic assessment of SAA mediated atherosclerosis found that SAA drove 
the expression of vascular cell adhesion molecules thus increasing inflammatory 
cell recruitment to the lesion (85).  This phenomenon is thought to contribute to 
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progression, but not initiation, of atherosclerosis as lipid deposition has been 
shown to precede leukocyte infiltration (15).  Thus, their model did not address 
SAA’s capacity to initiate the disease.   
 
Previous work from our lab also investigated the role of SAA in the 
development of atherosclerosis.  Vascular smooth muscle cells treated with 
recombinant SAA demonstrated a dose dependent increase in proteoglycan 
synthesis, primarily due to an increase in biglycan synthesis.  The SAA 
stimulated biglycan molecule had longer, more negatively charged 
glycosaminoglycan side chains (38).  This modification of biglycan is thought to 
increase LDL retention (17).  This effect on biglycan synthesis was shown to be 
TGF-β dependent as TGF-β inhibition nullified the observed increase in biglycan 
synthesis.  We repeated the experiment in a murine model of atherosclerosis by 
injecting apoe-/- mice with an adenoviral vector containing cDNA for human 
SAA1, a control adenoviral vector (ad-Null) or saline.  Mice injected with ad-
hSAA1 had dramatically increased plasma SAA after only three days.  
Interestingly, these mice also had dramatically increased TGF-β over the same 
timeframe.  After 28 days, western blot analysis of whole aortas demonstrated 
increased biglycan content in ad-hSAA1 injected mice, possibly predisposing the 
aorta to increased lipid retention and atherosclerosis (38).    This work 
represented the foundation of the experiments presented in this thesis. 
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1.5 Rationale for the studies presented 
 
Inflammation associated diseases such as diabetes and obesity are 
present in a very large portion of westernized societies.  Individuals suffering with 
such maladies have an increased risk of developing cardiovascular disease 
compared to age matched healthy peers though the exact etiology remains 
elusive.  A useful diagnostic tool to evaluate the extent of inflammation in these 
patients are assays for the plasma proteins hs-CRP and SAA.  Though much 
attention was given to hs-CRP and its potential causal role in atherosclerosis, no 
definitive causal association was determined.  Conversely, early working into 
SAA’s biology within the vasculature revealed several features that could 
potentiate cardiovascular disease.   SAA is found in lesions associated with 
apolipoprotein B and apolipoprotein A1 containing lipoproteins, it is chemotactic 
for molecules found in atherosclerotic lesions and it’s elevated in diseases known 
to confer greater risk of developing atherosclerosis.  One molecule for which SAA 
exudes potent synthetic upregulation is the small leucine rich, ubiquitously 
expressed proteoglycan biglycan (38).  Cells treated with recombinant SAA 
produced more biglycan, possessing long GAG chains and having a greater 
affinity for LDL particles.  SAA’s effects on biglycan synthesis were dependent on 
the action of TGF-β as inhibition of the cytokine with an inhibitory antibody 
resulted in no increase in biglycan synthesis compared with cells treated with 
SAA alone.  The previous experiments were conducted using a recombinant SAA 
molecule from Peprotech Inc. (NJ, USA).   This variant of SAA is a combination 
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of human SAA 1 and 2 with two amino acid substitutions.  Many of the pro-
inflammatory effects attributed to SAA have been deduced using this molecule 
for in vitro culture system analysis.   Recently, the Peprotech recombinant human 
SAA was directly compared with another Peprotech SAA variant, recombinant 
human SAA 1.  This molecule was based entirely on the human SAA 1 protein; 
however, it too has an amino acid substitution, thus a direct comparison to 
endogenous human SAA was not made.  The authors claim that the commonly 
used recombinant human SAA molecule is distinctly more inflammatory than the 
SAA variant based on human SAA 1 alone.  Their data suggested that 
recombinant human SAA 1 did not activate IL-8 or NF-κB to the same magnitude 
as the commonly used recombinant human SAA.  They conclude by stating that 
experiments using the recombinant forms of SAA should also be performed using 
endogenous forms for verification of the results (86).  We feel confident that the 
in vitro work using recombinant human SAA reflects SAA’s true biological 
functions as the data was corroborated in vivo using apoe-/- male mice, injected 
with an adenoviral vector containing the cDNA for human SAA1.  These mice 
exhibited a rapid induction of SAA with a concordant increase in TGF-β.  Western 
blot analysis 28 days after treatment revealed that there was an increase in 
vascular biglycan content.  Based on the response to retention hypothesis, an 
increase in modified biglycan within the subendothelial space of atherosclerosis 
prone arteries would increase the potential for increased lipid retention and 
atherosclerosis.  However, definitive evidence that an SAA mediated increase in 
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biglycan content would result in more plaque burden remained to be determined.  
Thus we set out to investigate the following model by testing five hypotheses: 
 
 SAA, expressed chronically would result in increased atherosclerosis   
 A brief increase in plasma SAA would also increase the development 
of atherosclerosis via upregulation of vascular biglycan content  
 Increased vascular biglycan is individually sufficient to increase 
atherosclerosis independent of inflammation  
 Vascular biglycan is required for the development of atherosclerosis  
 TGF-β is a necessary intermediate between SAA and biglycan in the 
development of SAA mediated atherosclerosis  
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Chapter 2: Materials and Methods 
 
2.1 Murine Models 
The work presented in this thesis utilized several murine models including 
the apolipoprotein E deficient (apoe-/-) mouse, the recombination activating gene 
1 x apolipoprotein E (rag1-/- x apoe -/-) double knockout, the biglycan transgenic 
and the biglycan x apolipoprotein E (bgn-/- x apoe -/-) double knockout.  The 
apoe -/- and the rag1 -/- mice were purchased from The Jackson Laboratory (stock 
# 002052 and stock # 003729, respectfully), and crossed in house to generate 
the rag1-/- x apoe -/- mouse.   The apoe -/- deficient mouse was utilized for all the 
SAA mediated atherosclerosis studies for two reasons.  First, apolipoprotein E 
can bridge lipoproteins to proteoglycans in a manner similar to SAA, thus 
interpretation of SAA’s role in lipoprotein retention would be difficult to isolate in 
the presence of apolipoprotein E.  Second, the apoe -/- mouse spontaneously 
develops atherosclerosis without the need for a high fat/high cholesterol diet, as 
these diets are capable of elevating SAA levels.   The deletion of the rag1 gene 
established a mouse unable to generate mature B and T lymphocytes, meaning 
the mouse had very little immune function present.  When the apoe -/- mouse was 
crossed to the rag1-/- mouse, it created an apoe -/- mouse tolerant to repeated 
adenoviral injections.   
Vascular biglycan content was elevated in mice with increased plasma 
levels of SAA.  However, SAA has multiple mechanisms by which it is suspected 
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to increase atherosclerosis.  Therefore, in the presence of SAA it was not 
possible to determine the exact individual role that elevated biglycan had on the 
development of atherosclerosis.  Therefore, the biglycan transgenic mouse was 
generated.  This mouse allowed elevated biglycan to be investigated 
independent of the other possible confounding factors associated with elevated 
SAA.  The biglycan transgene construct was created by inserting human biglycan 
cDNA downstream of the smooth muscle alpha actin promoter in the pBS-HSMA 
construct.   This construct was generously provided to us by Sasamura et al (87).  
It was immediately sent to Xenogen Biosciences (NJ, USA), were they performed 
microinjections of the construct into fertilized C57BL/6 ova.  Three founders, all 
male were returned to the University of Kentucky for further breeding.  No 
offspring resulted from in-house breeding with the male founders.  As a result, 
one male was shipped to Charles River Laboratory (MI, USA) for in vitro 
fertilization of C57BL/6 female mice.  Viable pups were produced, returned to the 
University of Kentucky and crossed with ldlr-/- mice.  Transgenic mice were 
identified by PCR using the following primer sequences:  forward primer, 5′-TCC 
TGG GAC TTC ACC CTG GA-3′ and reverse primer, 5′-TTG AAG TCA TCC TTG 
CGG AG-3′.  Mice positive for the transgene were bred together to establish the 
transgenic line, mice negative for the transgene were bred to establish wildtype 
control mice for the studies.  Interestingly, the difficulty we experienced             
establishing the biglycan transgenic mouse was not experienced by the original 
investigator.  Sasamura reported no fertility issues in generating this mouse.  We 
postulate that the increased biglycan content led to increased matrix deposition 
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and blockage of the vas deferens resulting in infertility of the three male 
founders. 
Preliminary studies revealed that elevated SAA resulted in increased 
vascular biglycan content which was hypothesized to increase atherosclerosis 
(38).   However, the absolute necessity of biglycan in SAA mediated 
atherosclerosis was not known, therefore the bgn-/- x apoe -/- double knockout 
was generated.  The bgn-/- mouse was kindly provided by Dr. Marian Young 
(National Institutes of Health). ).  bgn-/o males carry only a single copy of the 
gene for biglycan, located on the X chromosome.  In order to generate the bgn-/- 
x apoe -/-  double knockout mouse, males deficient in bgn-/-  were crossed to 
female apoe -/- deficient mice establishing biglycan wildtype males(bgn+/o)   and 
biglycan heterozygous (bgn+/-) females, that were now all heterozygous for 
apolipoprotein E (apoe +/-).  Male biglycan wildtype by apolipoprotein E 
heterozygous (bgn+/o x apoe +/-) were crossed to female biglycan x apolipoprotein 
E heterozygous mice (bgn+/- x apoe +/-).  The offspring from this cross provided 
the first opportunity to establish a male biglycan knockout mouse that was either 
deficient or heterozygous for apolipoprotein E (bgn-/o x apoe +/- or bgn-/o x apoe -/-
).  The previous cross also established a female mouse that was heterozygous 
for biglycan but deficient in apolipoprotein E (bgn+/- x apoe -/-).  The double 
knockout mouse was established by crossing the male biglycan deficient x 
apolipoprotein deficient  (bgn-/o x apoe -/-) to the female biglycan heterozygous x 
apolipoprotein E knockout (bgn+/- x apoe -/-).   
 
25 
 
 All studies were initiated in eight week old mice housed in specific 
pathogen free caging systems with 12 hour light/dark cycles in accordance with 
the University of Kentucky Animal Care and Use Committee.   
 
2.2 Human SAA1 adenoviral vector 
The human SAA1 and null adenoviral vectors were generated  
and kindly provided by Nancy Webb, University of Kentucky.  Briefly, cDNA for 
human SAA1 was cloned into the plasmid vector pAdCMVlink.  Plasmids which 
contained properly inserted cDNA were co-transfected into HEK293 cells with 
adenoviral DNA from H5.100CMVlacZ (88).  After 15 days, plaques were 
selected and screened by PCR.  Those plaques possessing SAA DNA were then 
further purified and used to produce a large scale preparation of the adenoviral 
vector stocks (89).    To commence the sustained SAA studies,  eight week old 
male rag1-/- x apoe-/- mice were injected via the lateral tail vein every 21 days with 
1.5 x 1011 plaque forming units of an adenoviral vector encoding human 
SAA1(ad-hSAA1),  a control empty adenoviral vector (ad-Null) or saline as 
previously reported (38).  The rag1-/- x apoe-/-   mice were utilized as the deletion 
of the rag1 gene made the mice tolerant to repeated viral injections necessary to 
facilitate chronic expression of SAA (model of sustained elevation in SAA).  For 
the brief elevation of SAA, eight week old apoe-/- male mice, also from Jackson 
Laboratory, received a single lateral tail vein injection of 1.5 x 1011 plaque forming 
units of ad-hSAA1, ad-Null or saline (model of brief elevation in SAA).  The bgn-/- 
x apoe-/- mice as well as the apoe-/- mice which received virus concurrently with 
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TGF-β inhibition also received a single injection of ad-hSAA1, ad-Null or saline 
as described above.  All experiments involving adenoviral vectors were 
performed in biological safety level II (BSL2) isolation cabinets following the 
Division of Laboratory Animal Research’s standard operating procedures.  To 
perform the injections, adenoviral stocks, either ad-hSAA1 or ad-Null, were 
transported on dry ice to the appropriate procedure room within the vivarium, 
equipped with a BSL2 safety cabinet.  The mice were assessed for overall health 
as part of a pre-enrollment screen prior to initiating the study.  Once all mice 
were deemed healthy, the supplies (syringes, alcohol swabs, etc.) were arranged 
in the hood in such a way as to minimize the time required to perform the 
injections as the virus was only stable for a few minutes once resuspended in 
sterile PBS.  For the injection, 100µl of sterile saline diluted viral stock was drawn 
into a 0.3cc insulin syringe with a 28 ½ gauge needle.  The mouse was then 
restrained in a rotating tail injector (Braintree Scientific; MA, USA) and the tail 
was warmed with a chemical hand warming pouch for 30 seconds. The lateral tail 
vein was visualized and the resuspended virus was injected into the mouse.  In 
the event that the vein became compromised do to mouse movement or needle 
infiltration, the contralateral vein was quickly accessed and injected.  The 
restraint was then loosened and hemodynamic control at the injection site was 
gained if necessary.  The mouse was then returned to its home cage and 
monitored for 20 minutes post injection.   
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2.3 TGF-β Neutralizing Antibodies 
 
Inhibition of TGF-β was utilized to determine the necessity of TGF-β in 
SAA mediated atherosclerosis.  We had previously shown in vitro that SAA 
increased biglycan in a TGF-β dependent manner (38).  However, it has yet to be 
determined if TGF-β is required for SAA mediated upregulation of biglycan in vivo 
and/or atherosclerosis; thus, we designed an experiment where SAA levels 
would be elevated in the presence or absence of TGF-β.   Inhibition of TGF-β 
was achieved using R and D Systems TGF-β 1, 2, 3 antibody (clone 1D11, 
MAB1835).  This antibody was selected as it was very specific to TGF-β, and did 
not affect other members of the TGF-β superfamily (90).  apoe-/- mice received 
antibody injections once concurrently with the administration of the adenoviral 
vectors; ad-hSAA1 or ad-Null.   The procedure for administration of SAA is 
described in Section 2.2, Human SAA1 adenoviral vector.  That procedure 
concluded with the mouse being removed from the tail vein injector and returned 
to the home cage.  For this experiment, the mouse would receive the tail vein 
injection, then immediately be removed from the restraint and be physically 
restrained by scruffing the excess skin between the shoulder blades while 
concurrently grasping the tail.  This position provided easy access to the midline 
of the ventral surface of the mouse. Once sufficient control of the animal was 
achieved it was injected intraperotineally with 1D11 antibody (2mg/kg) in sterile 
PBS via a 0.3cc syringe with a 28 ½ gauge needle.  As a control for the TGF-β 
inhibition, each study included a group of mice similarly injected with the 13C4 
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irrelevant control antibody (2mg/kg; GenScript, Piscataway, NJ, USA) also via 
the intraperotineal route.  The 13C4 antibody was directed against Shigella toxin 
and shown not to interfere with TGF-β signaling (91).  Mice were then returned to 
their home cage and monitored for 20 minutes. 
2.4 Diets 
 
For the studies investigating the role of SAA overexpression, all mice were 
maintained on normal rodent chow (product #8604) from Harlan Teklad.  
Throughout the study, mice had ad libitum access to food and water.  The 
Biglycan transgenic mice, crossed to the ldlr-/-  mouse on a C57BL/6 background,  
were fed “western diet” from Harlan Teklad (TD.88137).  The notable changes in 
this diet vs. standard chow are the high percent of calories from fat (42% vs. 
4.7% in normal chow) and 0.2% cholesterol.  The western diet was utilized for 
the transgenic studies as the biglycan transgenic x ldlr-/- mouse required dietary 
modification to develop atherosclerosis (92).  Because of the high fat content of 
the “western” diet, it would spoil quite rapidly.  As such, fresh food was provided 
every three to four days.  Mice ate approximately 4 grams of food per day.   
2.5 Blood collection 
 
For all studies, blood was collected via submandibular vein route for all 
samples except the terminal blood collection.  The submandibular approach is 
preferred when small volumes of blood are required with short intervals between 
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collections.  In the SAA studies, blood was collected on days 0, 1, 3, 7, 10, 14, 
21, 28 and then weeks 8, 12 and 16, depending on the duration of the study.  
The increased frequency of collection of blood at the beginning of the studies 
allowed for the accurate determination of human SAA, murine SAA and TGF-β 
levels, as these molecules tend to have rapid induction with an equally rapid 
reduction in plasma concentration.  However, the increased frequency of blood 
collection required that we staggered the mice such that not all mice were bled at 
each timepoint.  For example, if a study group had 9 mice; then the first 3 would 
be bled on day 0, the next three on day 1 and the final three on day 3.  The 
staggered approach to blood collection prevented the use of repeated measures 
analysis as the data did not represent each mouse at each timepoint.  For the 
biglycan transgenic study, blood was collected at day 0 and then at weeks 4, 8 
and 12.  To collect the blood, unanesthatized mice were scruffed by the excess 
skin between the shoulder blades to immobilize the mouse’s head.  The 
submandibular vein typically resides just caudal and slightly superior to the 
sebaceous gland located just caudal to the mandible.  The skin was lanced 
superficially with a 5mm stainless steel lancet (Medipoint; NY, USA).  As blood 
began to flow it was collected in EDTA treated tubes.  Once an appropriate 
volume of blood had been collected, pressure was applied to the wound until 
hemostasis was achieved.  The animal was then returned to its home cage and 
monitored for 20 minutes.  Terminal blood was collected by cardiac puncture for 
all studies.  At the conclusion of all studies, mice were adequately anesthetized 
and a thoracotomy performed to gain access to the heart.  A 1.0cc syringe with a 
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28 gauge needle was inserted into the right ventricle and approximately 1ml of 
blood was collected.  All blood samples were stored on ice until they could be 
centrifuged to separate the plasma from the red blood cells.  All analyte 
measurements were performed on plasma. 
 
2.6 Plasma analyte measurements 
 
Blood samples were collected throughout all studies described in this 
thesis.  For studies involving the sustained overexpression of SAA, the 
concentration of the following analytes were measured: human and mouse SAA, 
TGF-β, total cholesterol and triglycerides.   For studies involving the brief 
overexpression of SAA, the concentration of the following analytes were 
measured: human and mouse SAA, TGF-β, total cholesterol, triglycerides and 
liver alanine transaminase.   For the biglycan transgenic study, TGF-β, total 
cholesterol and triglycerides were measured.  Human and mouse SAA were 
measured by species specific ELISA from Anogen Corp. (EL10015) and 
Invitrogen (KMA0021) respectfully.  TGF-β was measured by the Promega TGF-
β1 Emax ImmunoAssay System (G7590).  Cholesterol (Cholesterol E) and 
triglycerides (L-Type TG M) were measured via colorimetric assay using kits from 
Wako Diagnostics (Richmond, VA).   Alanine transaminase was measured using 
Therma Scientific Infinity ALT/GPT assay reagent.  All assays were performed 
per manufacture’s instruction.  A BioRad X-mark spectrophotometric plate reader 
was utilized to determine analyte concentration. 
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2.7 Western Blot 
 
Vascular tissue was homogenized in Trizol reagent (Invitrogen; NY, USA) 
and proteins purified per the manufacturer’s protocol.  Proteins were treated with 
Chondroitinase ABC to digest the glycosaminoglycan side chains of the 
proteoglycans overnight at 37°.  Total protein was measured using the Lowry 
method and equal amounts of protein from each sample was then separated on 
4-20% precast gradient gels (Bio-Rad; CA, USA) at 150 volts for 45 minutes.  
The samples were then transferred to PVDF membranes at 100 volts for 90 
minutes.  The membranes were then probed for biglycan (AF2667, R & D 
systems, 1:1000) or the loading control β-actin (A2066, Sigma-Aldrich; MO, USA, 
1:1000).  The membranes were then incubated with horseradish peroxidase 
conjugated secondary antibody at 1:25,000 dilution and proteins detected by film 
exposure using West Pico Super Signal chemiluminescent detector (34080, 
Pierce; IL, USA).   Densitometry was performed on individual bands using 
imageJ (NIH, USA) software’s western blot analysis plug-in. 
2.8 Atherosclerosis analysis 
 
The aortic sinus, brachiocephalic artery and whole aorta from the 
ascending arch to the iliac bifurcation were collected at the conclusion of all 
studies.  Aortic roots and brachiocephalic arteries were frozen in a cryogenic 
cutting compound and sectioned at 10um thickness using a Leica CM1850 
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cryostat.  Collection of aortic root sections began once all three valve leaflets of 
the aortic valve were in view and proceeded distally away from the valves 
towards the ascending aorta.  Sections were collected in series such that each 
aortic root was collected on eight slides containing nine sections each.  Each 
section on an individual slide was 80µm from the previous section.  Given that 
the brachiocephalic artery is longer than the aortic root, a total of 12 sections per 
slide were collected across eight slides.  The start point of brachiocephalic artery 
collection was the convergence of the right subclavian artery and the right 
common carotid. Once this point was reached sections were collected proximally 
towards the heart. Again, the sections were 80µm apart on each slide. 
 
Prior to staining, aortic root and brachiocephalic sections were allowed to 
dry at room temperature and then fixed in 10% neutral buffered formalin for 5 
minutes.  Lipids were visualized by staining the sections with Oil Red O’ (O0625, 
Sigma-Aldrich; MO, USA) for 20 minutes as previously described (34).  Sections 
were then counterstained with Mayer’s Hematoxyin (26043, Electron Microscopy 
Sciences; PA, USA) and coverslipped.  Aortic root (4x magnification) and 
brachiocephalic artery (10x magnification) sections were visualized using a Nikon 
Eclipse 80i bright field microscope and Nikon Digital Sight Ri1 camera.  One slide 
from the aortic root and brachiocephalic artery from each mouse was quantified, 
thus nine aortic root sections and twelve brachiocephalic sections were 
quantified per mouse.  Using Nikon NIS elements software suite, all lesions per 
tissue section were traced and summed to generate the total lesion area per 
33 
 
section.  After all nine (aortic root) or twelve (brachiocephalic) sections were 
measured, they were averaged to give an average lesion area per mouse.  Data 
were then presented as the average lesion area for each mouse as well as the 
group average.   
 
Whole aortas were cleaned in vivo and removed from the mice and fixed 
in 10% neutral buffered formalin overnight, then transferred to saline prior to en 
face analysis to soften the tissue.  Using very fine tipped spring scissors, the 
vessels were first cut along the greater curvature of the aortic arch distal to just 
past the left subclavian bifurcation.  The aorta was then cut along the lesser 
curvature from the ascending arch to the iliac bifurcation. The tissue was then 
pinned en face in premade black wax dishes and stained with 1% Sudan IV 
(S4261, Sigma-Aldrich; MO, USA) dissolved in 70% ethanol/acetone for 20 
minutes.  The aortas were washed several times with PBS, and then visualized 
using a Nikon SMZ800 stereo microscope with a Nikon Digital Sight DSFi1 
camera.   
 
For en face analysis, the aortic arch is analyzed.  To establish the total 
arch area, a line extended 3mm from the left subclavian artery bifurcation distally 
along the aorta.  A line is then created perpendicular to the aorta along the end of 
the 3mm line.  Any tissue superior to this line was considered part of the total 
aortic arch area and used in quantification.  The first en face measurement is the 
total area achieved by simply tracing the entire perimeter of the tissue previously 
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identified as arch.  Then each lesion is traced and surface area summed to 
establish total lesion area.  Data were presented as the percent lesion area for 
each mouse as well as the mean for each group.  All data was analyzed by 1-
way ANOVA.   
 
2.9 Fluorescent Immunohistochemistry 
 
Aortic root and brachiocephalic sections were immunostained with 
antibodies against murine biglycan (AF2667,R & D systems R & D systems, 
1:50), apolipoprotein B (K23300R, Biodesign, 1:50), Perlecan (BMDV10187, 
Accurate, 1:100), CD68 (ab53444, Abcam, 1:100) and smooth muscle alpha 
actin (NB300-978, Novus, 1:50) as previously described (53).  Sections were 
then probed with host specific secondary antibodies conjugated to either 488nm 
or 594nm fluorophore (Jackson ImmunoResearch) and counterstained with 
Vectashield mounting media containing DAPI (H-1200, Vector Labs).  Sections 
were visualized fluorescently via a Nikon Eclipse 80i fluorescent microscope or a 
Leica AOBS TCS SP5 inverted laser scanning confocal microscope.   
 
2.10 Bright field Immunohistochemistry 
 
Aortic root sections were incubated with primary antibodies for murine 
biglycan (AF2667, R & D systems), then incubated with a biotinylated secondary 
antibody (Jackson ImmunoResearch).  The presence of biglycan antigen was 
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visualized using an AEC chromogen kit (SK-4205, Vector Labs) and 
counterstained with Meyers hematoxilyn (26043, Electron Microscopy Sciences; 
PA, USA).  Images were captured using a Nikon Eclipse 80i light microscope at 
4x and 20x magnification.   
 
2.11 LDL binding assay with apoe-/- VSMC’s 
 
Primary vascular smooth muscle cells were isolated from ~3 week old 
apolipoprotein E (apoe-/-, stock # 002052) mice and grown to confluence without 
passaging. Cells were incubated with SAA (25µg/ml) isolated from acute phase 
murine plasma (kindly provided by Frederick and Maria de Beer, University of 
Kentucky) ± TGF-β neutralizing antibody 1D11 (10µg/ml, MAB1835, R & D 
Systems; Minneapolis, MN) or control antibody 13C4 (10µg/ml, GenScript, 
Piscataway, NJ) for 24 hours.  The cells were washed and then labeled with 
Alexa-fluor 594 (A10237; Life Technology; Grand Island, NY) labeled LDL 
(0.5mg/ml) for 2 hours at 4°C.  Cells were washed twice in cold PBS, fixed in 4% 
formaldehyde and then coverslipped with Vectasheild mounting media containing 
DAPI (H-1200, Vector Labs).  The cells were then imaged using a Nikon Eclipse 
80i fluorescent microscope.  For each experimental condition, 5 20x fields were 
captured in both the 594nm and the 405nm channels and quantified using 
ImageJ software (93).  LDL binding is expressed as Alexa-fluor 594 surface area 
normalized to DAPI surface area from 5-10 20x microscope fields.  Negative 
controls included wells with no cells and/or no Alexa-fluor 594 labeled LDL.   
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2.12 Fast performance liquid chromatography 
 
Terminal plasma samples (50ul) were separated for analysis of lipoprotein 
cholesterol content chromatographically using a BioRad Biologic Duoflow FPLC 
machine equipped with a Superose size exclusion column. Fractions, each 
containing about 200µl of eluate were collected on a BioRad Biofrac fraction 
collector and assayed for total cholesterol as previously described (93) using a 
Wako Diagnostic Cholesterol E colorimetric assay kit.   
 
2.13 Statistical analysis 
 
Statistical differences were assessed by one-way ANOVA to assess 
effects of treatment with ad-hSAA1, ad-Null or saline; or two-way ANOVA to 
assess effects of ad-hSAA1 or ad-Null ± 1D11 or 13C4.   LDL binding was 
assessed using a student’s t-test.  Linear regression was used to assess the 
relationship between vascular biglycan and aortic sinus atherosclerosis.   P<0.05 
was considered statistically significant.   
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Chapter 3: Sustained elevation of SAA results in increased 
atherosclerosis   
3.1 Results 
 
We previously investigated the effect of SAA on vascular smooth muscle 
cells.  Cells treated with increasing doses of SAA had a dose-dependent 
increase in biglycan synthesis as well as increased binding affinity of biglycan for 
LDL.  SAA’s effect on biglycan synthesis was recapitulated in vivo in apoe-/- mice 
injected with an adenoviral vector containing the gene for human SAA (38). 
Interestingly, the effect of SAA was inhibited by concurrently treating the cells 
(38) or mice (Thompson et al, in submission) with a TGF-β inhibitory antibody.   
We hypothesized, based on the response to retention hypothesis, that the 
increased vascular biglycan would lead to increased lipoprotein retention in the 
vessel wall stimulating the development of atherosclerosis.  To test this 
hypothesis, rag1-/- x apoe -/-mice were injected with ad-hSAA1, ad-Null or saline 
once every 21 days for 12 weeks.  rag1 deficiency was necessary for the animals 
to tolerate repeated viral injections.  These mice had persistently elevated human 
SAA throughout the study (Figure 3.1A) with no difference in murine SAA 
between groups at any timepoint (Figure 3.1B), indicating that our experimental 
manipulations did not induce an endogenous inflammatory response.  We 
previously determined in vitro that SAA's increase in vascular biglycan content 
was TGF-β dependent (38).  Thus we measured TGF-β in all groups to determine 
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in vivo whether elevated SAA had any effect on TGF-β levels. Mice that received 
ad-SAA also had increased TGF-β compared to ad-Null and saline injected mice 
throughout the study (Figure 3.2).Consistent with Dong et al, ad-hSAA1 treated 
mice had increased atherosclerosis on the aortic intimal surface (Figure 3.3A, 
p<0.001) and within the brachiocephalic artery (Figure 3.3B, p<0.05) compared 
with ad-Null or saline groups.  There was a strong trend towards increased 
atherosclerosis in the aortic root in ad-hSAA1 treated mice compared to ad-Null 
or saline groups; however it did not reach statistical significance (Figure 3.3C, 
p=0.09).  Biglycan and apoB co-localized in aortic sinus lesions, further 
supporting the response to retention hypothesis (Figure 3.4).  The induction of 
human SAA had no effect on plasma cholesterol or triglycerides (Figure 3.5AB).  
Lipoprotein distribution was measured using fast performance liquid 
chromatography and did not differ between any of the groups (Figure 3.5C). 
Body weight did not differ at any point throughout the study (data not shown).
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Figure 3-1: Human, but not murine SAA increased when mice 
received multiple injections of ad-hSAA1 compared to 
control mice 
rag1-/- x apoe-/- male mice were injected with ad-hSAA1 (black circles), ad-Null 
(open squares) or saline (black triangles) every 21 days (as indicated by the 
red numerals on the x axis) and fed normal rodent chow for 12 weeks.  A. 
Mice receiving ad-hSAA1 had a dramatic, persistent elevation of human 
SAA1. Shown are mean ± SEM for n=2-5 per group.   B. Murine SAA did not 
increase nor did it differ between groups throughout the study. Shown are 
mean ± SEM for n=2-7 per group. 
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Figure 3-2:  Murine TGF-β increased in mice injected with ad-hSAA1  
rag1-/- x apoe-/- male mice were injected with ad-hSAA1 (black circles), ad-Null 
(open squares) or saline (black triangles) every 21 days (indicated by red 
numerals on the x axis) and fed normal rodent chow for 12 weeks.   Ad-hSAA1 
injected mice had persistently increased TGF-β throughout the study 
compared to mice injected with ad-Null or saline. Shown are means ± SEM 
from n= 2-6 mice/group per timepoint.  
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Figure 3-3: Atherosclerosis increased in mice chronically 
overexpressing human SAA   
rag1-/- x apoe-/- male mice were injected with ad-hSAA1 (black circles), ad-Null 
(open squares) or saline (black triangles) every 21 days and fed normal rodent 
chow for 12 weeks.  Ad-hSAA1 injected mice had increased atherosclerosis 
on the aortic intimal surface (A) and in the brachiocephalic artery (B). There 
was a trend towards increased atherosclerosis in the aortic root that did not 
reach significance (C). Data points represent individual mice with the 
horizontal bar representing means of n =4-16 mice per group analyzed by 1-
way ANOVA and Tukey’s multiple comparisons test. *p<0.05, **p<0.01. 
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Figure 3-4:  Biglycan and apolipoprotein B colocalized in rag1-/- x    
apoe -/- murine aortic sinus lesions 
rag1-/- x apoe-/- male mice were injected with ad-hSAA1, ad-Null or saline 
every 21 days and fed normal rodent chow for 12 weeks.  Representative 
confocal image of a shoulder lesion in an aortic root from an ad-hSAA1 
injected rag1-/- x apoe-/- mouse (magnified 40x).  ApoB and biglycan were 
visualized with green and red fluorescent antibodies respectfully.  Co-
localization is indicated by yellow.   Image is representative of 4-5 mice per 
group.  Asterisk is within the lumen of the vessel, scale bar 50µm. 
* 
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Figure 3-5: Chronically elevated hSAA1 did not affect plasma lipids  
rag1-/- x apoe-/- male mice were injected with ad-hSAA1, ad-Null or saline 
every 21 days and fed normal rodent chow for 12 weeks.  After 12 weeks, 
there was no difference in plasma cholesterol (A, n=9-11 mice per group) or 
triglycerides (B, n=8-10 mice per group). A & B data presented as mean ± 
SEM analyzed by 1-way ANOVA and Tukey’s multiple comparisons test.   
Lipoprotein distribution was measured in plasma from n=4-5 mice per group 
collected after 12 weeks of study and separated by FPLC.  No differences 
were observed between groups [C, ad-hSAA1 (black circles), ad-Null (open 
squares) or saline (black triangles), data presented as mean ± SEM].  
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3.2 Discussion:  
 
Persistently elevated human SAA in rag1-/- x apoe-/- mice resulted in 
increased atherosclerotic lesion area.  There were no differences between 
groups in cholesterol or triglyceride levels, and the adenovirus did not induce 
endogenous inflammation demonstrated by the lack of elevation of murine SAA.   
Mice that received ad-hSAA1 had dramatically elevated TGF-β compared to mice 
receiving ad-Null or saline.   
 
Biglycan is thought to be the proteoglycan most responsible for the 
retention of pro-atherogenic lipoproteins in the vessel wall leading to the 
development of atherosclerosis (9).  Thus we propose that at least one 
mechanism by which SAA is pro-atherogenic is by induction of vascular biglycan 
in a TGF-β dependent manner leading to increased retention of atherogenic 
lipoproteins.  The co-localization of apolipoprotein B with biglycan in a shoulder 
lesion of the aortic sinus supports this concept. 
However, the exact role of TGF-β in atherosclerosis remains quite 
controversial.  Mallat et al used an inhibitory antibody to decrease TGF-β content 
and observed increased plaque size in apoe-/- male mice.  They also reported a 
much more inflamed plaque with increased macrophage content and a decrease 
in collagen fibers (54).   Similarly, Lutgens et al reported that TGF-β inhibition in 
apoe-/- male mice via injection with a soluble TGF-β receptor resulted in a 
dramatic change in lesion cellularity with an influx of inflammatory cells.  
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However, when lesions were analyzed for atherosclerosis, the group receiving 
TGF-β inhibition had a striking decrease in lesion area (56).   To add to the 
confusion surrounding TGF-β in atherosclerosis, we have previously shown that 
ldlr-/- mice infused with angiotensin II (angII) for 28 days had increased vascular 
biglycan content.  We also demonstrated that the increased biglycan content was 
TGF-β dependent, (similar to SAA induction of biglycan) as the inhibition of TGF-
β  in the setting of angII infusion resulted in less vascular biglycan and less 
atherosclerotic lesion area.  However, there was no change in inflammatory cell 
content within lesions (53).   Thus further study into the role of elevated TGF-β in 
our SAA overexpression model is necessary to elicit its exact role in SAA 
mediated atherosclerosis. 
 
Our results support the previous findings from Dong et al (85) that SAA is 
proatherogenic.  In their study, murine SAA was overexpressed by lentiviral 
vector leading to significantly increased atherosclerosis on the aortic intimal 
surface and the aortic sinus in chow fed apoe-/- mice.  The increased 
atherosclerosis coincided with upregulation of vascular adhesion molecules and 
chemotactic factors capable of increasing leukocyte migration into 
atherosclerosis susceptible regions of arteries.  The study presented here 
addresses events prior to vascular wall leukocyte infiltration, including vascular 
wall remodeling and lipoprotein retention (9).  Our model indicated that SAA is 
acting on the vasculature prior to the cascade of inflammatory events observed in 
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Dong’s work.  We have shown that treatment with SAA, both in vitro and in vivo, 
increased vascular biglycan content leading to increased lipid retention.   
 
In further support of the hypothesis that lipid retention precedes 
inflammatory infiltration of atherosclerosis prone regions of arteries, Nakashima 
et al investigated human coronary vessels to establish a chronology of events 
thought to provoke atherosclerosis development.  In a very effective use of 
histology and immunohistochemistry, their study demonstrated very convincingly 
that lipid retention preceded leukocyte infiltration in the development of lesions in 
human coronary arteries.   They investigated vessels from individuals whose 
average age of death was 36 years.  These individuals died from trauma or other 
non-cardiovascular causes.  In all the lesions investigated, diffuse intimal 
thickening (DIT), the non-pathologic remodeling of the vessel wall preceded  both 
lipid and macrophage infiltration.  They identified several locations in the 
coronary artery were there was DIT but no lesion development; however, they 
did not find regions with lesions and no DIT. The deposition of matrix was clearly 
an initial step in the development of atherosclerosis.  They also demonstrated 
that lipid accumulation became quite substantial in regions with DIT prior to 
macrophage infiltration suggesting that lipid retention preceded the inflammatory 
response in the development of atherosclerosis, strongly supporting our model of 
atherosclerosis development (15).  Thus, our work taken together with Dong’s 
data suggest that SAA’s actions leading to the development of atherosclerosis 
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may be multifactoral in nature, playing a role in both early (lipid retention) and 
more advanced lesion development (inflammatory infiltration). 
Changes in the vessel wall, such as diffuse intimal thickening prior to fatty 
streak formation are thought to be paramount in the development of 
atherosclerosis in regions of the vessel prone to lipid deposition (94).  In diffuse 
intimal thickening there is a dramatic increase in subendothelial matrix deposition 
including proteoglycans such as biglycan which we observed in our model and is 
thought to play a major role in lipid retention in atherosclerotic lesions.  The 
vasculature is divided into two groups based on the presence or absence of 
diffuse intimal thickening.  First are the atherosclerosis prone vessels such as the 
aorta, carotids and coronaries.  In humans, these vessels all exhibit diffuse 
intimal thickening as early as late fetal development (16).  Conversely 
atherosclerosis resistant arteries are located much farther down the vascular tree 
and tend to deliver blood to specific organs such as the splenic and hepatic 
arteries.  Observations of these vessels reveal no diffuse intimal thickening at 
any timepoint observed (16).    Though there is not always atherosclerosis at 
sites of diffuse intimal thickening, in the human vasculature there are is always 
subendothelial matrix expansion including increased biglycan at sites of 
atherosclerosis (15).   
 
Beyond the observation that SAA increases biglycan deposition in a 
proatherogenic manner, it has been reported that SAA co-localized with both 
biglycan and apolipoprotein B containing lipoproteins (83).  SAA has amino acid 
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clusters that allow it to simultaneously bind proteoglycans and lipoproteins  which 
could make SAA directly atherogenic via directing the binding of lipoproteins  to 
biglycan in the subendothelial space of atherosclerosis prone arteries(95) .  
Certainly more research is required to demonstrate that SAA is directly mediating 
such an interaction.   Thus, SAA could contribute to atherosclerosis through 
multiple mechanisms, including vascular wall remodeling, by directing 
chemotaxis of circulating leukocytes to the region of lipoprotein retention (85), 
and by potentially bridging lipoproteins to vascular wall proteoglycans (83) (95). 
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Chapter 4: Briefly elevated SAA resulted in increased 
atherosclerosis  
4.1 Results 
 
We have clearly shown that sustained elevation of SAA is proatherogenic 
(Chapter 3), providing a possible link between chronic inflammatory diseases and 
the increased risk of cardiovascular disease.  However, many people have 
dramatic, albeit brief increases in SAA via an acute phase response to infection 
or injury (96-98).  Survivors of such an event have increased long term all cause 
mortality, including cardiovascular disease.  Thus we sought to determine if a 
brief increase in SAA also increased atherosclerosis, as we have previously 
demonstrated that even a brief increase in SAA resulted in increased vascular 
biglycan content (38).  To test the hypothesis that even brief exposure to 
increased SAA was proatherogenic, apoe-/- mice received a single injection of 
Ad-hSAA1, Ad-Null or saline at the initiation of the study.  The mice that received 
ad-hSAA1 had a dramatic increase in human SAA, albeit not to the level seen in 
an acute phase response.  The increased human SAA returned to baseline levels 
in less than two weeks (Figure 4.1A).  Murine SAA did not differ between groups 
at any timepoint (Figure 4.1B).  In mice that received ad-hSAA1 there was a 
transient increase in TGF-β that resolved in a similar timeframe to human SAA 
(Figure 4.2).   Interestingly, despite only observing a  transient increase in human 
SAA levels, these mice developed significantly more atherosclerosis on the aortic 
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intimal surface (Figure 4.3A, p<0.001), the aortic root (Figure 4.3B, p<0.05) and 
the brachiocephalic artery (Figure 4.3C, p<0.05) compared with ad-Null or saline 
treated mice.  This result could be explained by the fact that mice receiving ad-
hSAA1 had increased vascular biglycan content at the conclusion of the study 
even though SAA was only increased for a brief period of time (Figure 4.4).  The 
induction of human SAA had no effect on terminal plasma lipids (Figure 4.5AB).   
Lipoprotein distribution was measured using fast performance liquid 
chromatography, and no differences were observed between groups (Figure 
4.5C).  Body weight measured at the completion of the study did not differ 
between groups (Figure 4.6A).  Alanine transaminase (ALT) was measured for 
the first two weeks of the study to determine if injecting the mice with an 
adenoviral vector that traffics to the liver led to hepatitis.  There was a brief 
increase in ALT in the mice receiving ad-hSAA1 that did not exceed the normal 
range of 5-60 U/L typically observed in mice (Figure 4.6B).  The ad-Null and 
saline groups did not deviate from baseline ALT values.  Aortic root sections 
were double stained for BGN and apoB and immunofluorescent analysis 
demonstrated colocalization of apolipoprotein B with biglycan within the vascular 
wall (Figure 4.7).  To determine if the retention of ApoB containing lipoproteins by 
vascular matrix is a direct result of increased plasma SAA, primary apoe-/- aortic 
vascular smooth muscle cells were incubated with mouse SAA for 24 hours, 
followed by incubation with Alexa-594 labeled LDL for two hours.  Cells treated 
with SAA had a 4 fold increase in LDL binding compared to cells not treated with 
SAA (Figure 4.8A).   To determine if the role of TGF-β in SAA mediated 
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lipoprotein retention, the experiment was repeated with the additional conditions; 
SAA + TGF-β inhibitory antibody 1D11 or SAA + 13C4 irrelevant control 
antibody.  In the absence of TGF-β signaling, the amount of bound LDL was 
significantly reduced compared to SAA treated cells (Figure 4.8B).  
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Figure 4-1:  Human, but not murine SAA increased in mice that received a 
single injection of ad-hSAA1 compared to control mice  
apoe-/- male mice were injected at day 0 with ad-hSAA1 (black circles), ad-Null 
(open squares) or saline (black triangles) and fed normal rodent chow for 16 
weeks.   Mice receiving a single injection of ad-hSAA1 had a dramatic albeit 
transient increase in human SAA1. (A, data presented as mean ± SEM for n=2-
3 mice per group).  All groups had a small, transient increase in murine SAA.  
(B, data presented as mean ± SEM for n=2-6 mice per group). 
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Figure 4-2: TGF-β increased dramatically in mice overexpressing 
SAA  
apoe-/- male mice were injected with ad-hSAA1 (black circles), ad-Null (open 
squares) or saline (black triangles) and fed normal rodent chow for 16 weeks.  
TGF-β was transiently but dramatically increased in ad-hSAA1 mice compared 
to ad-Null or saline mice.  Data presented as means ± SEM from n= 4-6 mice 
per group.   
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Figure 4-3: A brief elevation of human SAA1 was associated with 
increased atherosclerosis after 16 weeks 
apoe-/- male mice were injected with ad-hSAA1, ad-Null or saline and fed 
normal rodent chow for 16 weeks. Atherosclerosis was measured at three 
sites: the aortic intimal surface (A), the brachiocephalic artery (B) and the 
aortic sinus (C).  Data points represent individual mice with the horizontal bar 
representing means of n =4-16 mice per group analyzed by 1-way ANOVA with 
Tukey’s multiple comparisons. *p<0.05. 
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Figure 4-4: A brief increase in human SAA1 resulted in increased 
vascular biglycan content after 16 weeks.  
apoe-/- male mice were injected with ad-hSAA1, ad-Null or saline and fed normal 
rodent chow for 16 weeks.  Carotid arteries were collected and immunoblotted for 
biglycan (BGN) or actin (A) then analyzed by densitometry using ImageJ 
software (B). Each lane shows protein from an individual mouse; densitometry 
shows means ± SEM for 5-7 mice per group analyzed by one-way ANOVA and 
Tukey’s multiple comparisons.  *p<0.05. 
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Figure 4-5:  Briefly elevated human SAA1 did not alter plasma lipids or 
lipoprotein distribution  
apoe-/- male mice were injected once with ad-hSAA1 , ad-Null or saline.  After 16 
weeks, total cholesterol (A) and triglycerides (B) did not differ between groups. Data 
presented as mean ± SEM for 4-18 mice per group analyzed by one-way ANOVA and 
Tukey’s multiple comparisons. The distribution of lipoproteins did not differ between 
groups (C), data represent mean ± SEM for n=2-9 mice per group, ad-hSAA1 (black 
circles), ad-Null (open squares), saline (black triangles).   
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Figure 4-6:  Body weights did not differ; however, ALT increased 
slightly as a result of increased human SAA1 compared to 
control mice.   
apoe-/- male mice were injected once with ad-hSAA1, ad-Null or saline.  Body 
weight did not differ between groups at the conclusion of the study (A).  Data 
represent mean ± SEM for n=4-11 mice analyzed by one-way ANOVA and 
Tukey’s multiple comparisons.  Mice injected with ad-SAA had a slight increase 
in ALT liver enzymes compared to mice injected with either ad-Null or saline 
(B).  Data represent mean ± SEM for n=2-3 mice per group. 
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Figure 4-7:  Biglycan and apolipoprotein B co-localized in aortic 
sinus lesions of mice overexpressing human SAA1. 
An atherosclerotic lesion in an aortic root from an ad-hSAA1 injected 
apoe-/- mouse was double stained for apoB (green) and biglycan (red). 
Co-localization is indicated by yellow. Shown is a confocal image 
magnified 63X, representative of 4 mice. The asterisk indicates the lumen 
of the aortic sinus.  Scale bar 10µm. 
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Figure 4-8  VSMC cultures treated with murine SAA had increased TGF-β 
dependent LDL binding  
apoe-/- aortic VSMC cultures were treated with vehicle or SAA for 24 hours, then 
washed and incubated with Alexa-594 labeled LDL (0.5mg/ml) for 2 hours. LDL 
binding is expressed as Alexa-fluor 594 surface area normalized to DAPI surface 
area quantified by fluorescent microscopy using ImageJ software (NIH, USA). A. 
SAA treated cells had significantly increased LDL binding compared to controls. 
Data analyzed by student’s t-test.  B. To determine the role of TGF-β in LDL 
retention, apoe-/- aortic VSMCs were treated with vehicle, SAA or SAA with the TGF-
β neutralizing antibody 1D11 or control antibody 13C4.  1D11 prevented the SAA 
increase in LDL binding; there was no effect of 13C4. Data are presented as 
mean±SEM from 5-10 20x regions/condition analyzed by one-way ANOVA and 
Tukey’s multiple comparisons.  *p<0.05 **p<0.01.  Controls included cells treated 
with 1D11 inhibitory antibody or 13C4 antibody without concurrent SAA treatment. 
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4.2 Discussion 
In this model, we investigated the potential atherogenic effect of a single 
transient increase (<14 days) of ad-hSAA1, such as seen in an intensive care 
hospitalization.  Similar to mice with sustained overexpression of SAA, mice in 
this study had increased atherosclerosis at all three vascular sites investigated.  
Furthermore biglycan and apolipoprotein B co-localized in aortic sinus lesions of 
mice exposed to a brief increase in SAA.  Also similar to the sustained elevation 
group, these mice had no metabolic variability in such lipid parameters as 
cholesterol, triglycerides or lipoprotein distribution to explain the difference in 
atherosclerosis.  Thus, this increase in atherosclerosis is presumably driven 
directly by increased SAA.   It is noteworthy to point out that the atherosclerosis 
data for the aortic intimal surface appears to be biphasic.  The data for the mice 
receiving ad-hSAA1 appears to form two unique groups, one with a much higher 
average lesion area than the other, suggesting that the mice in the lower group 
did not respond to the administration of ad-hSAA1 to the same degree as those 
in the high atherosclerosis group.  This could be considered a confounding factor 
in concluding that SAA is universally causing the development of atherosclerosis.  
However, the aortic sinus and brachiocephalic atherosclerosis data looks 
normally distributed such that the aortic intimal surface is likely an anomaly.   
This study investigated the role of acutely increased SAA and its effect on 
atherosclerosis.  This induction of SAA, though lower in total plasma SAA 
concentration, is similar in duration to what a human could experience during an 
acute phase response to infection or injury.  However, in our study, we utilized an 
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adenoviral vector to mediate increased SAA gene expression rather than LPS or 
sodium nitrate, which would increase plasma SAA, but also broadly stimulate the 
innate immune system.  The adenoviral method avoided introducing the milieu of 
inflammatory cytokines seen in LPS or sodium nitrate stimulated immune 
response that would make it nearly impossible to elicit SAA’s individual effect on 
atherosclerosis.  A better understanding of the impact of brief but significant 
inflammation is necessary as clinical data suggests that individuals suffering 
acute severe illness resulting in intensive hospitalization have increased mortality 
post discharge (96-98) .  These patients have increased SAA as part of the APR 
experienced in the hospital, thus it is plausible that the increased mortality, 
particularly related to cardiovascular disease could be driven by the downstream 
effects of elevated SAA.  This idea is supported by a study investigating 
myocardial infarct (MI) and progression of atherosclerosis.   Dutta et al 
investigated the potential for MI, with the associated APR, to accelerate the 
development of atherosclerosis.  The common dogma of atherosclerosis 
following MI is that the disease progression continued at the pre- MI rate.  This 
assumption failed to consider the risk of acute inflammation, thus they 
investigated the possibility that MI related inflammation could alter the 
progression of atherosclerosis.  Using an apoe-/- mouse model of left coronary 
artery ligation, they compared atherosclerosis development between infarcted 
and sham operated animals.  The data demonstrate that mice in the MI group 
had a subsequent increase in atherosclerosis, likely the result of the acute phase 
response to the infarct leading to increased monocyte recruitment to the 
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developing lesions (99).  Our work here investigated SAA, a single component of 
the acute phase response and its role in the development of atherosclerosis.  It is 
certainly possible that the increased atherosclerosis observed in Dutta’s study 
was in part the result of increased SAA during the post MI acute phase response.  
SAA is known to be chemotactic for macrophages, thus SAA in the lesion could 
have explained the observed increase in monocyte recruitment.  Thus SAA’s 
elevation in the acute inflammatory response following MI could certainly 
contribute to accelerated atherosclerosis (78).   It is also well established beyond 
just myocardial infarction that brief but significant episodes of in-hospital 
inflammation increases mortality after discharge.  Brinkman et al analyzed data 
from intensive care units (ICU) which treated patients admitted for many different 
illnesses.  They determined that post-discharge mortality was much higher for 
ICU discharged patients than age and gender matched non hospitalized 
individuals (100).   Thus, we propose that beyond indicating risk, elevated 
plasma SAA plays a causal role in atherosclerosis development and prevention 
of increased SAA may be a therapeutic target.  A number of currently available 
agents can lower SAA including statins.  Individuals with a history of myocardial 
infarction and elevated plasma SAA are at greater risk for a second 
cardiovascular event than similar patients with lower SAA. However, treatment 
with pravastatin reduced the increased risk, perhaps in part by lowering SAA, 
(though SAA levels were not a specific endpoint of the study and thus were not 
individually analyzed) (101). Given the pleiotropic effects of statins it is difficult to 
dissect the mechanisms by which they lower CVD risk.  However, it is possible 
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that beyond lowering LDL cholesterol, statins may have beneficial effects by 
lowering SAA.  Beyond statins, other approaches have been found to lower SAA, 
such as weight loss (72) and aspirin based therapies (102).  However, further 
clinical research is necessary to validate SAA as a therapeutic target in humans, 
and to determine if therapies targeted specifically to elevated SAA in humans can 
be protective.   
To summarize, we have shown that both sustained and brief elevations of SAA 
result in increased atherosclerosis.   We propose that SAA is increasing vascular 
biglycan content, resulting in increased lipid retention in the vasculature leading 
to increased atherosclerosis.  To examine the specific role of increased vascular 
biglycan independent of manipulation to plasma SAA, we developed a mouse 
model overexpressing biglycan under the control of the smooth muscle α actin 
promoter. 
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Chapter 5:  Biglycan overexpression and atherosclerosis  
5.1 Results 
In our models of sustained and briefly increased SAA, mice developed 
increased atherosclerosis.   Biglycan, whose vascular content is increased by 
SAA, is thought to play a central role in the development of atherosclerosis by 
retaining apolipoprotein B containing lipoproteins in the subendothelial space of 
atherosclerosis prone arteries.  The purpose of the following experiment was to 
determine if increased biglycan, such as seen following an increase in SAA, was 
individually sufficient to increase atherosclerosis, independent of any potential 
confounding factors introduced by elevated SAA.  This study utilized the biglycan 
transgenic mouse.  For a detailed description of the mouse model, please review 
section 2.1, Murine models.  At eight weeks of age, male and female biglycan 
transgenic x ldlr-/- and control mice were fed western diet for 12 weeks.  The 
presence or absence of the transgene had no effect on body weight; however, 
male mice significantly out gained females in both genotypes (Figure 5.1).   
Similar to body weights, the presence of the transgene did not affect total 
cholesterol; however, there was a significant difference between male and 
female mice (Figure 5.2A).  Interestingly, the transgene did affect plasma 
triglycerides.   Gender as well as genotype resulted in significant changes; again 
males had higher triglycerides as did mice not carrying the transgene (Figure 
5.2B).  FPLC fractionation revealed that lipoprotein profiles did not differ between 
genotypes (Figure 5.3).  TGF-β was elevated with western diet, but did not differ 
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between transgenic and non-transgenic mice (Figure 5.4).  Atherosclerosis was 
analyzed at three sites; the aortic intimal surface, the aortic sinus and the 
brachiocephalic artery.  There were no differences in atherosclerotic lesion area 
between genders, so male and female mice within genotypes were combined for 
analysis.  Biglycan transgenic mice had increased atherosclerosis on the aortic 
intimal surface (Figure 5.5A, p<0.05) and in the aortic sinus (Figure 5.5B, 
p<0.006).  There was no difference in atherosclerosis measured in the 
brachiocephalic artery (Figure 5.5C) after 12 weeks; however, there was a trend 
towards increased atherosclerosis in the brachiocephalic artery in mice analyzed 
after four weeks of diet (data not shown).  Such regional and chronological 
differences in the development of atherosclerosis are well described in the 
literature and could certainly explain the lack of atherosclerosis in the 
brachiocephalic artery (103).   
 
Immunohistochemical analysis of aortic root sections demonstrated 
increased biglycan content in transgenic mice (figure 5.6A).  Vascular biglycan 
content was measured by western blot (Figure 5.6B) and was increased in 
transgenic mice, which correlated with the aortic sinus lesion area (Figure 5.6C, 
p<0.0001).  Biglycan is thought to be a key mediator of lipid retention in the 
vessel wall, so aortic root sections were double labeled with biglycan and apoB 
antibodies.  Mice transgenic for biglycan had increased co-localization with apoB 
containing lipoproteins (Figure 5.7).  To further test the effect of increased 
vascular biglycan, vascular smooth muscle cells were cultured from transgenic 
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and wildtype aortas and incubated with fluorescently labeled LDL.   There was a 
strong trend towards increased binding in cells from mice possessing the 
biglycan transgene; however, it did not reach significance (Figure 5.8).   
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Figure 5-1:  Biglycan transgenic male mice gained less weight than 
control males; however, genotype did not affect female 
weight gain 
Biglycan transgenic x ldlr-/- and control mice were fed a western diet for 12 
weeks (Control male, closed square; Control female, open square; transgenic 
male, closed circle; transgenic female, open circle).  Body weight was measured 
at the indicated timepoints throughout the study.  Control male mice gained 
significantly more weight by week 8 compared to biglycan transgenic mice.  This 
effect persisted for the duration of the study.  Body weight in female control mice 
did not differ from biglycan transgenic females at any time throughout the study. 
Data shown is mean ± SEM for n=11-16 per group analyzed by two-way 
repeated measures ANOVA with Bonferroni multiple comparisons.  * p<0.05, ** 
p<0.001 
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Figure 5-2:  Biglycan transgenic mice had lower triglycerides compared 
to control mice; however, there was no difference in 
cholesterol 
Biglycan transgenic (BGNtg) and control mice were fed a western diet for 12 
weeks.  Plasma collected at the end of 12 weeks was analyzed for cholesterol 
and triglycerides.  Cholesterol did not differ between transgenic and control mice; 
however, male transgenic mice did have higher total cholesterol than female 
transgenic mice (A).  Data shown is mean ± SEM for n=12-16 mice per group, ** 
p<0.01.  Triglycerides differed between transgenic and control mice, between 
male and female transgenic mice, and between male and female control mice 
(B).  Data shown is mean ± SEM for n=12-16 mice per group. Data analyzed by 
two-way ANOVA with Bonferroni multiple comparisons.  **p<0.01, ***p<0.001. 
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Figure 5-3: Lipoprotein cholesterol distribution did not differ 
between biglycan transgenic and control mice.  
Biglycan transgenic (BGNtg, closed circles) and control (open squares)  mice 
were fed a western diet for 12 weeks.  Terminal plasma samples were 
separated by fast performance liquid chromatography to analyze lipoprotein 
distribution.  No difference was observed between transgenic animals (black 
circle) and controls (open squares).  Data shown is mean ± SEM for n=3-4 
mice per group.  
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Figure 5-4: TGF-β measured after 12 weeks on study did not differ 
between biglycan transgenic and control mice 
Biglycan transgenic (BGNtg) and control mice were fed a western diet for 12 
weeks.  Terminal plasma was collected and assayed for TGF-β.  No difference 
was observed between transgenic and control mice.  Data shown is mean ± 
SEM for n=9-13 mice per group analyzed by two-way ANOVA with Bonferroni 
multiple comparisons.  
 
 
71 
 
 
 A
or
tic
 L
es
io
n
ar
ea
 (%
 )
BGNtg  Control
0
10
20
30 p<0.05
 
At
he
ro
sc
le
rs
ot
ic
le
si
on
  a
re
a 
(µ
m
2 )
BGNtg Control
0
200,000
400,000
600,000 p<0.006
 
 
At
he
ro
sc
le
rs
ot
ic
 le
si
on
 a
re
a 
(µ
m
2 )
BGNtg Control
0
50,000
100,000
150,000
200,000
250,000
 
 
Figure 5-5: Biglycan transgenic mice had increased atherosclerosis in the 
aortic sinus and on the aortic intimal surface 
Biglycan transgenic (BGNtg, closed circles) and control mice (closed squares) 
were fed a western diet for 12 weeks.  Transgenic mice had increased 
atherosclerosis on the aortic intimal surface (A) and in the aortic sinus (B). There 
was no difference atherosclerosis between transgenic and control mice in the 
brachiocephalic artery (C).  Lesions were analyzed using Nikon NISelements 
software. Data points represent individual mice with the horizontal bar 
representing means of n =20-25 mice per group analyzed by students t-test. 
*p<0.05. 
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Figure 5-6: Biglycan transgenic mice had increased vascular 
biglycan content which correlated with aortic root lesion 
area 
Biglycan transgenic (BGNtg) and control mice were fed a western diet for 12 
weeks.  Aortic root sections from biglycan transgenic and control mice were 
immunostained for biglycan, revealing a striking increase in biglycan content in 
transgenic mice (A).  Shown are representative images from n=3-4 mice per 
group.  Total protein from carotid arteries was immunoblotted for biglycan to 
determine the extent of transgene expression.  The data revealed an increased 
in vascular biglycan content in transgenic mice (B).  The magnitude of increased 
vascular biglycan correlated strongly with aortic sinus atherosclerosis in both 
transgenic and control mice (C, r2=0.29, p<0.0001).   
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Figure 5-7: Biglycan and apolipoprotein B co-localized to a greater 
extent in biglycan transgenic mice compared to control 
mice 
Biglycan transgenic and control mice were fed a western diet for 12 
weeks.  Representative confocal images of a shoulder lesion from 
biglycan transgenic (BGNtg) and control mouse aortic root section 
(magnified 40x).  Apolipoprotein B (apoB) and biglycan (BGN) were 
visualized with red and green fluorescent antibodies respectfully. Nuclei 
were stained blue with DAPI.   Co-localization is indicated by the 
presence of yellow in the merged image.   Images are representative of 
n=4-10 per group.  Asterisks indicate the lumen of the vessel. 
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Figure 5-8:  Vascular smooth muscle cell cultures from biglycan 
transgenic mice did not differ in LDL binding compared 
to control mice 
Vascular smooth muscle cells from biglycan transgenic and control aortas 
were cultured in chamber slides to near confluence.  Cells were then 
incubated with Alexafluor-594 labeled LDL for two hours at 4oC.  Bound 
LDL was quantified by quantitative fluorescent microscopy and 
normalized to total DAPI area.  Biglycan transgenic animals had a trend 
towards increased LDL binding; however, it did not reach significance.  
Data are presented as mean±SEM for n=5-10 regions/condition analyzed 
by students t-test.  
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5.2 Discussion 
Ldlr-/- mice expressing the transgene for human biglycan and wildtype 
controls were fed a western diet for 12 weeks.  Mice possessing the biglycan 
transgene had increased atherosclerosis in the aortic sinus and on the aortic 
intimal surface compared to wildtype mice.  Atherosclerotic lesion area did not 
reach significance in the brachiocephalic artery after 12 weeks of western 
diet.   
 
Biglycan has been proposed to be a key mediator of lipid retention in 
both murine and human atherosclerosis.  It is found in atherosclerotic lesions 
and we and others have demonstrated its colocalization with apolipoprotein B 
containing lipoproteins.  Many mechanisms have been shown to increase 
vascular biglycan content.  Individuals with diabetes for instance have 
increased biglycan expression (104), and peptides and cytokines such as 
angiotensin II (105), and serum amyloid A (38) also lead to increased 
vascular biglycan content.   Biglycan synthesized under stimulation of such 
cytokines had longer, more negatively charged glycosaminoglycan side 
chains that interacted more strongly with the positively charged amino acid 
repeats on the surface of apolipoprotein B (17).  However, diabetes and these 
cytokines have other potential atherogenic effects.  For instance, 
hyperglycemia has been shown to down regulate eNOS derived NO in 
vascular endothelial cells (106),   which in turn led to activation of the NF-kB 
inflammatory pathways.    AngII is a small peptide best studied in the renin-
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angiotensin system of blood pressure regulation.  However, angII has a 
potent proinflammatory effect on vascular cells found within lesions leading to 
induction of many cytokines linked to the development of atherosclerosis 
(107).   SAA has been described extensively in this thesis and it too can 
stimulate the expression of many proinflammatory cytokines known to 
activate cells found in lesions.  Thus to truly identify the potential role of 
biglycan in the development of atherosclerosis, the biglycan transgenic 
mouse model was created.  It allowed for the study of lipid retention mediated 
by vascular biglycan independent of other confounding factors that could also 
stimulate lesion development.   
 
It has been demonstrated that biglycan synthesis under the influence 
of inflammatory cytokines has increased glycosaminoglycan (GAG) chain 
length with increased sulfate incorporation (38).  Here biglycan synthesis was 
under the control of the smooth muscle alpha actin promoter and not elevated 
cytokines.  Thus it could be argued that the study did not accurately reflect 
the environment previously described in biglycan mediated lipid retention.  
We did not measure GAG chain length or sulfate incorporation in the 
transgenic animal.  However, this study was performed in ldlr-/- mice fed a 
proinflammatory western diet meaning that the mice may have been in an 
inflamed state, and biglycan synthesized under these conditions may have 
had changes in the GAG chains; however, since control mice were under the 
same conditions they would have the same response.   
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  One potentially confounding factor in the analysis of atherosclerosis in 
this study was the elevated triglycerides in the littermate control animals.  
Triglycerides are well documented as a marker of cardiovascular disease and 
their increase is seen as a robust indication of disease risk (108).   Individuals 
that receive intensive statin therapy, in which their LDL cholesterol levels 
decreased to clinically optimal levels still had continued risk of acute coronary 
events if dyslipidemia in the form of hypertriglyceridemia remained (109), 
suggesting the elevated triglycerides are an independent risk factor for CVD.  
This risk may be due to the association of triglycerides with atherogenic 
lipoproteins and lipoprotein remnants, especially those carrying apo C-III 
(110).   Typically these remnant particles are quickly cleared by the liver; 
however, in hypertriglyceridemia, the clearance is greatly reduced and the 
accumulation of triglyceride rich particles on endothelial cells has been 
documented (111).  These particles then translocate to the subendothelial 
space, binding proteoglycans in the matrix and enhance the retention of 
proatherogenic lipoproteins.   Thus the mechanism by which triglycerides may 
enhance atherosclerosis is slightly different from traditional lipid retention; 
however, the end product is subendothelial lipoprotein particle retention.  
Taken together the increased triglycerides supports our model as the 
increase in both vascular biglycan and translocation of triglyceride rich 
particles ultimately ends with increased lipoprotein retention and increased 
transit time in the subendothelial space leading to the milieu that drives the 
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inflammatory component of atherosclerosis.   These findings lend credence to 
triglyceride’s causal role in atherosclerosis; however, clinical data has not fully 
supported triglycerides as an independent risk factor (109).  Statin 
monotherapy  has been shown to decrease triglycerides and LDL-C; 
however, statins have many functions beyond lipid lowering and a clear 
reduction in CVD based explicitly on the reduction in triglycerides has yet to 
be proven (112) (113).  Other classes of drugs are also effective at lowering 
triglycerides.  Both niacin and fibrates have been shown to reduce 
triglycerides in dyslipidemca individuals.  Both drugs in large trials as 
monotherapies for the reduction of CVD have been shown to reduce both 
triglyceride levels and acute cardiovascular events; however, the effect of 
lower triglycerides has not been clearly shown to drive the decrease in CVD 
(114) (115) .   Given that significantly increased atherosclerosis was observed 
in the transgenic animals compared to the wildtype controls whose 
triglycerides were elevated, the role of triglycerides will not alter the 
conclusion that proteoglycan mediated retention of lipoproteins is responsible 
for the increase in atherosclerosis.   
 
The purpose was to determine if increased biglycan content was 
individually sufficient to increase atherosclerosis over control mice.  The data 
indicated that biglycan was increased in transgenic mice as was the extent of 
atherosclerotic lesion development.   Thus increased biglycan is pro-
atherogenic likely by increasing the retention of proatherogenic lipoproteins.   
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This data supports a role for biglycan in the development of atherosclerosis; 
however, it remains to be seen whether biglycan is absolutely necessary for 
the development of atherosclerosis.  To determine this, further studies were 
conducted using biglycan/apolipoprotein E double knockout mice injected with 
ad-hSAA1 or controls.  
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Chapter 6: Biglycan deficiency and atherosclerosis  
6.1 Results  
 
Many studies have suggested a proatherogenic role for biglycan; 
however, its absolute requirement for the development of atherosclerosis has 
not been investigated.  Here we investigate the necessity of biglycan in 
atherosclerosis.  Biglycan deficient mice, five times backcrossed to the low 
density lipoprotein receptor knockout mouse on a C57BL/6 background, were 
obtained from Williams et al (Thomas Jefferson University, Philadelphia, PA, 
USA) and crossed with apoe-/- mice from Jackson Laboratory.  Generating 
this mouse was challenging as the bgn-/o males carry only a single copy of the 
gene for biglycan, located on the X chromosome.  In order to generate the 
bgn-/- x apoe -/-  double knockout mouse, males deficient in bgn-/o  were 
crossed to female apoe -/- deficient mice establishing biglycan wildtype 
males(bgn+/o)   and biglycan heterozygous (bgn+/-) females, that were now all 
heterozygous for apolipoprotein E (apoe +/-).  Male biglycan wildtype by 
apolipoprotein E heterozygous (bgn+/o x apoe +/-) were crossed to female 
biglycan x apolipoprotein E heterozygous mice (bgn+/- x apoe +/-).  The 
offspring from this cross provided the first opportunity to establish a male 
biglycan knockout mouse that was either deficient or heterozygous for 
apolipoprotein E (bgn-/o x apoe +/- or bgn-/o x apoe +/-).  The previous cross 
also established a female mouse that was heterozygous for biglycan but 
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deficient in apolipoprotein E (bgn+/- x apoe -/-).  The double knockout mouse 
was established by crossing the male biglycan deficient x apolipoprotein 
deficient (bgn-/o x apoe -/-) to the female biglycan heterozygous x 
apolipoprotein E knockout (bgn+/- x apoe -/-).  Littermate control mice were 
established by crossing a male mouse possessing a single copy of biglycan 
but deficient in apolipoprotein E (bgn+/o x apoe -/-) to a female homozygous for 
expression of biglycan while deficient in apolipoprotein E (bgn+/+ x apoe -/-) 
There was an immediate and persistent phenotype observed with the 
bgn-/- x apoe-/- mice.  Approximately 80% of offspring born to bgn-/- x apoe-/-
 females exhibited hydrocephaly and required euthanasia by the third week of 
life.  However, the 20% of offspring that reached weaning age while 
remaining asymptomatic for hydrocephaly appeared to be healthy for the 
duration of their life.  We have successfully crossed the bgn-/- mouse to the 
ldlr-/- mouse for studies investigating the role of biglycan in a model of 
angiotensin II mediated atherosclerosis  (29).  These mice exhibited no 
obvious health issues, thus the combination of biglycan deficiency and 
hyperlipidemia cannot explain the health issues observed in the bgn-/- x   
apoe-/-.  This study utilized the bgn-/- x apoe-/-and apoe-/- male mice that 
survived to eight weeks of age.  Both the bgn-/- x apoe-/-and apoe-/- mice were 
injected once with ad-hSAA1 or ad-Null and fed normal rodent chow for 16 
weeks.  Human SAA increased dramatically in the ad-hSAA1 injected mice 
(Figure 6.1 A).  Strikingly, bgn-/- x apoe-/-mice receiving ad-hSAA1 had 
significantly more atherosclerosis in the aortic sinus compared to bgn-/- x 
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apoe-/- ad-Null injected mice (Figure 6.1B).  The bgn-/- x apoe-/- mice injected 
with ad-hSAA1 had a trend toward increased atherosclerosis on the aortic 
intimal surface compared to bgn-/- x apoe-/- ad-Null injected mice (Figure 
6.1C).   
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Figure 6-1:  Biglycan deficiency, combined with elevated hSAA1 resulted 
in increased atherosclerosis 
bgn-/o x apoe-/- and bgn+/o x apoe-/- were injeced once with ad-hSAA1 or ad-Null (ad-
hSAA1 DKO, closed circle; ad-hSAA1/control, closed square; ad-Null/DKO, open 
cirlce; ad-Null/control, open square) and bled at the timepoints indicated.  Human 
SAA1 was measured by species specific ELISA.  Mice receiving ad-hSAA1 had 
dramatically elevated human SAA1 (A).  Data shown is mean ± SEM for n=3-11 mice 
per group.  Atherosclerosis, after 16 weeks, was significantly increased in bgn-/- x 
apoe-/-  ad-hSAA1 injected mice in the aortic sinus (B)  Data shown are mean ± SEM 
for n=7-9 mice per group,  p<0.05.  There was a trend towards increased 
atherosclerosis in bgn-/- x apoe-/-  ad-SAA injected mice on the aortic intimal surface 
(C)  Data shown is mean ± SEM for n= 6-7 analyzed by two-way ANOVA with 
Bonferroni multiple comparisons.  *p<0.05 
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6.2 Discussion 
The analysis of this study was stopped as concerns about the mice 
enrolled in the study became more apparent.  The bgn-/- x apoe-/- double 
knockout mouse was produced in our colony by initially crossing biglycan 
deficient males to apolipoprotein E deficient females.  As biglycan is an X-
linked gene, generation 1 offspring were all heterozygous or wildtype; the 
lines were then split such that knockout and littermate controls were produced 
from the same founders.  This was the same strategy our lab used to produce 
the  bgn-/- x ldlr-/-  double knockout (93).  However, the combination of 
biglycan deficiency and apolipoprotein E deficiency resulted in hydrocephaly 
rates for pre-weaned double knockout offspring greater than 80%.  It took 
much longer than initially anticipated to enroll the study because of the 
extensive amount of breeding required.  
 
 Initial analysis also revealed some atherosclerosis patterns that were 
not observed in other studies that made us believe we were observing a 
possible “healthy survivor” effect, also known as survivorship bias (116).   
This statistical concept can be applied to many fields from finance to meta-
analysis of medical studies.  Basically we are biasing our data by not 
considering the mice that did not survive and thus the probability that they 
may have somehow influenced the data differently than what we actually 
observed.  Given the excessive mortality we may have been sampling a sub-
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population of double knockout mice that was very different from the double 
knockout population as a whole, making it impossible to draw conclusions 
about the entire population.   Both bgn-/- x apoe-/- and apoe-/- mice injected 
once with ad-hSAA1 had a profound increase in human SAA levels compared 
to mice injected with ad-Null, and the human SAA did not return to baseline 
levels for more than 8 weeks.  Previous experiments using apoe -/- mice and a 
single injection of ad-hSAA1 have consistently shown resolution in human 
SAA levels by 10-14 days post injection.  Interestingly, in this study, apoe -/-  
mice with a prolonged increase in human SAA did not have increased 
atherosclerosis in the aortic sinus or on the aortic intimal surface compared to 
ad-Null injected apoe -/-  mice.  This too is quite different than in previous 
studies as ad-hSAA1 injected mice consistently had more atherosclerosis 
than ad-Null mice.  This study also failed to recapitulate the atherosclerosis 
data within the littermate controls.  In previous work from our lab, apoe -/-  
mice that received ad-hSAA1 consistently had more atherosclerosis at all 
three site of atherosclerosis analysis compared to mice receiving ad-Null.  
However, in this study the two groups have almost identical levels of 
atherosclerosis in their aortic sinus and on their aortic intimal surface.   
 
The hypothesis that SAA is proatherogenic is supported by not only 
this thesis but also by Dong et al that revealed increased SAA alone was 
sufficient to increase atherosclerosis (85).  Furthermore, we hypothesized that 
biglycan deficiency would be atheroprotective.  Biglycan is found in both 
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murine and human lesions and co-localizes with apolipoprotein B containing 
lipoproteins (36).  It is the basis for the well supported “response to retention” 
hypothesis of atherosclerosis that states that lipoprotein retention by 
proteoglycans, particularly biglycan, is an initiating event in the development 
of atherosclerosis.   Recently we published that increased biglycan resulted in 
increased atherosclerosis using a biglycan transgenic  model {Chapter 5 & 
(93)}.  Thus, we hypothesized that the absence of biglycan should attenuate 
SAA mediated lesion development.  However, data in our bgn-/- x apoe-/- mice 
demonstrated that biglycan deficiency in the presence of elevated SAA is 
proatherogenic.  These mice had significantly more atherosclerosis in the 
aortic sinus than controls (p<0.05). There was a trend towards increased 
atherosclerosis on the aortic intimal surface that did not reach significance.  
This data, though contradictory to our overall hypothesis in the lab that 
biglycan is pro-atherogenic, is becoming more supported.  In unpublished 
data from another study examining biglycan deficiency in diabetic ldlr-/- mice 
we observed an increase in atherosclerosis in mice deficient in biglycan 
compared to mice expressing bgn regardless of glycemic status (data not 
shown).  The likely confounding factor in biglycan deficiency seems to be 
proteoglycan compensation.  Biglycan is a very relevant molecule responsible 
for biological processes from initial development in utero through 
maintenance of collagen fibers, teeth and bones throughout adult life (30).   
Previous work in our lab examined the role of angiotensin II on the 
development of atherosclerosis in biglycan deficient and biglycan wildtype 
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mice crossed to ldlr-/- mouse on a C57BL/6 background.  We demonstrated 
that mice lacking biglycan actually developed more atherosclerosis compared 
to biglycan wildtype mice.  Further analysis revealed that perlecan; another 
vascular proteoglycan, is upregulated and co-localizes with apolipoprotein B 
containing lipoproteins in the biglycan deficient mice.  This perlecan 
upregulation is not observed in biglycan wildtype mice nor is it TGF-β 
dependent as the treatment of these mice with the TGF-β inhibitory antibody 
1D11 did not alter perlecan’s expression (29). These data suggest that 
perlecan can compensate for biglycan’s absence by achieving the same if not 
greater degree of lipoprotein retention in the vessel wall.  However, 
interpretation of this data is complicated by the fact that perlecan is thought to 
not play a role in the development of human atherosclerosis and is in fact 
down regulated in human disease (117).     
 
Another possible contributor to increased atherosclerosis in biglycan 
deficiency is TGF-β.   Hyperglycemia, increased AngII and increased SAA 
have all been shown to increase TGF-β.   Interestingly TGF-β is maintained in 
its latent state in the matrix by interactions with biglycan (44) and decorin 
(118).  Thus, the absence of biglycan could allow for increased available 
active TGF-β, as we have previously shown (53).  However, as discussed in 
the introduction section 1.4.1, TGF-β has such complex and interconnected 
signaling pathways that deducing its exact role in a particular disease may be 
beyond the scope of our current technologies (48).  
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These data, though not conclusive, do point to the concept that biglycan may 
not be necessary for the development of atherosclerosis.  To further 
investigate our mechanism for the development of atherosclerosis, the role of 
TGF-β was investigated using an apoe-/- mouse model of atherosclerosis 
coupled with TGF-β inhibition.    
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Chapter 7: The necessity of TGF-β signaling in SAA 
mediated atherosclerosis  
7.1 Results 
 
We have previously demonstrated that both brief and sustained elevations 
of SAA directly increased atherosclerosis.  Our data suggests that increased 
atherosclerosis resulted from SAA increasing TGF-β which in turn increased 
vascular biglycan content followed by an increase in lipid retention.  We have 
previously shown in vitro that inhibition of TGF-β prevented SAA induction of 
vascular biglycan content (38); however, the downstream effect of TGF-β 
inhibition on the development of atherosclerosis remains unknown.  Thus, we 
now aimed to determine the necessity of TGF-β in SAA-induced atherosclerosis.   
For this study, eight week old male apoe -/- mice were injected once with 
ad-hSAA1 or ad-Null via tail vein method, and simultaneously injected via 
intraperotineal route with the TGF-β inhibitory antibody 1D11 or 13C4 control 
antibody.  Human and murine SAA were measured throughout the study using 
species specific ELISA’s.  Human SAA increased only in the ad-hSAA1 group 
receiving 13C4 control antibody (Figure 7.1 A).  Murine SAA did not differ 
between groups at any timepoint (Figure 7.1 B).  Subsequent data analysis was 
stopped given the lack of SAA expression in the ad-hSAA1/1D11 group.   
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Certainly the question could be asked as to whether the concurrent 
administration of 1D11 with ad-hSAA1 specifically could have resulted in the 
inability of the virus to infect the mice.  However, we had previously carried out a 
very small pilot study investigating SAA’s effect on vascular biglycan content in 
the absence of TGF-β signaling. In that study apoe-/- male mice were injected 
with ad-hSAA1 or ad-Null and then concurrently injected with either 1D11 or 
13C4; and vascular tissues collected 28 days later.  This pilot SAA/1D11 study 
utilized the same lot of ad-hSAA1 that all other studies presented here utilized.  
Plasma was collected for measurement of human SAA and TGF-β at several 
early timepoints.  Ad-hSAA1 administration increased human SAA to levels well 
within what we typically see when administering ad-hSAA1 without 1D11 (Figure 
7.2A).  The data clearly demonstrates that 1D11 antibody did not affect the 
expression of human SAA in these mice.  Levels of TGF-β were undetectable in 
the mice receiving 1D11 indicating that antibody was fully functional as well 
(Figure 7.2A).  Furthermore, western blot analysis of aortas taken 28 days after 
administration of ad-Null, ad-hSAA1, ad-hSAA1 + 1D11 or ad-hSAA1 + 13C4 
revealed a striking decrease in biglycan synthesis in mice receiving 1D11, 
compared to mice receiving ad-hSAA1 + 13C4 (Figure 7.2B).  So based on this 
small study the administration of ad-hSAA1 and 1D11 do not interfere with one 
another.   
 To attempt to resolve this issue, another small study was performed using 
eight week old apoe-/- male mice from The Jackson Laboratory (Bar Harbor, 
Maine, USA).  apoe-/- mice (n=12) were divided into three groups.  The first group 
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received a single injection of ad-hSAA1 and acted as a control for the expression 
of SAA.  The second group was injected with ad-hSAA1 via tail vein and then 
concurrently injected with 1D11 antibody via IP route.   For 1D11 to truly be an 
issue, the antibody would likely have to alter a pathway involved in SAA secretion 
from hepatocytes as the virus is being delivered intravenously and would likely 
bind to and infect the hepatocytes prior to the antibody being absorbed into the 
lymphatics and then systemic circulation where it could interfere with the virus 
directly.  There are no documented TGF-β dependent SAA secretory pathways 
described in the literature so this is either not the issue or would represent a 
novel interaction between human SAA and antibodies against murine TGF-β.   
The third group was injected with ad-hSAA1 and then 24 hours later received an 
IP injection of 1D11.  This group investigated the possibility of 1D11 inhibitory 
antibody to destabilize SAA in circulation such that it is rapidly cleared.  If such 
an effect is taking place the SAA levels in this delayed 1D11 group should be 
much lower than the ad-hSAA1 only group on day three indicating the increased 
SAA clearance.  Plasma was analyzed from samples collected on days 0, 1 and 
3 to determine the time course expression of human SAA.  All three groups had 
dramatically, equivalently elevated expression of SAA over the first three days 
(Figure 7.3).  This experiment demonstrates that 1D11 does not interfere with 
SAA expression and thus we have not resolved why the 16 week SAA 1D11 
experiment failed. This research is ongoing. 
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Figure 7-1: Human SAA1 did not increase in mice concurrently 
injected with ad-SAA and TGF-β inhibitory antibody 1D11 
apoe-/-  mice were injected once with ad-hSAA1 or ad-Null and concurrenlty 
injected with either TGF-β inhibitory antibody 1D11 or 13C4 control antibody 
(ad-hSAA1/1D11, closed circle; ad-hSAA1/13C4, closed square; ad-
Null/1D11, open cirlce; ad-Null/13C4, open square)  and bled at the timepoints 
indicated.  Human and murine SAA were measured by species specific ELISA.  
Only mice receiving ad-hSAA1 + 13C4 had dramatically elevated human 
SAA1 (A).  Data shown is mean ± SEM for n=3-9 mice per group.  Murine SAA 
did not differ between groups at any timepoint (B).  Data shown is mean ± 
SEM for n=2-9 mice per group. 
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Figure 7-2:  TGF-β inhibitory antibody 1D11 suppressed TGF-β 
expression, resulting in decreased vascular biglycan 
content in mice concurrently injected with ad-hSAA1 
and 1D11 antibody. 
apoe-/-  male mice, eight weeks of age, were injected with ad-hSAA1 or ad-
Null and simultaneously injected with either the TGF-β inhibitory antibody 
1D11 or control antibody 13C4 via IP route.  Human SAA (black columns) 
was measured by species specific ELISA.  No difference in SAA was 
detected in mice 1 day after receiving ad-hSAA1 regardless of the presence 
or absence of TGF-β antibody (A)  Data shown is mean ± SEM for n=4-5 mice 
per group analyzed by one-way ANOVA with Tukey’s multiple comparisons.  
TGF-β (open columns) was elevated in mice receiving ad-hSAA1 with or 
without 13C4 control antibody.  However, mice receiving 1D11 antibody had 
no detectable TGF-β, similar to ad-Null injected mice (A).  Data shown is 
mean ± SEM for n=4-5 mice per group analyzed by one-way ANOVA with 
Tukey’s multiple comparisons.  Aortas were collected 28 days after injections 
and immunoblotted for biglycan (BGN) or actin. 1D11 prevented the ad-
hSAA1 induction of vascular biglycan but 13C4 had no effect (B).  Each lane 
shows protein from an individual mouse representative of n=4-5 mice per 
group.   
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Figure 7-3:  TGF-β inhibitory antibody 1D11 did not affect 
human SAA expression in ad-SAA injected 
mice. 
Eight week old male apoe-/- mice were injected with ad-SAA 
(closed circle), ad-SAA + 1D11 (open square) or ad-SAA + 1D11 
24hrs after ad-SAA (delayed group, closed triangle).  Plasma was 
drawn at the indicated timepoints and assayed for human SAA.  
All mice had rapid induction of human SAA regardless of the 
presence or timing of administration of the TGF-β inhibitory 1D11. 
Data shown is mean ± SEM for n=4 mice per group.   
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7.2 Discussion:  
 
apoe-/- deficient male mice were injected with ad-hSAA1 or ad-Null 
concurrently with either TGF-β inhibitory antibody 1D11 or an irrelevant control 
antibody 13C4.  However, the group receiving ad-hSAA1 concurrently with 1D11 
did not have the anticipated increase in human SAA as seen in the ad-hSAA1 
mice concurrently injected with 13C4.  There are several possible explanations 
for this.  First could be a problem with the adenovirus’ ability to infect the mice.   
The virus is very sensitive to freeze thaw cycles and must be stored correctly, 
transported to the animal room correctly and resuspended as close to 
administration of the injections as possible.  The virus is stored in a -80o freezer. 
When aliquots are removed from the freezer, they are immediately placed on dry 
ice for transport to the animal facility.  In my preparation to do adenoviral 
injections, this is always the last step so as to minimize the time the virus is out of 
the freezer.  Once everything in the animal facility is set-up to perform the 
injections the virus is resuspended in sterile saline, then immediately injected into 
the animals.  This has been my ritual for every set of injections I have done.  I 
have utilized the tail vein injection procedure for hundreds of injections.  I have a 
great deal of experience with tail vein injections and make notes as part of the 
animal record as to the quality of the injection such that a mouse can be removed 
based on poor delivery of the virus on my part.  So it does not appear to be a 
procedural deficiency that led to the lack of SAA expression.  Thus, it is highly 
unlikely that one of these steps resulted in the absence of SAA expression.  The 
adenoviral construct was produced in the Webb lab as previously described (89).  
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They have extensive knowledge of large scale adenoviral production and 
storage.  All viral aliquots are immediately stored in a designated -80 freezer 
once prepared.  Throughout our lab’s investigation of SAA’s effects on 
atherosclerosis we have used aliquots of the same large scale viral prep 
produced in the Webb lab.  This implies that all steps from production to initial 
storage were taken appropriately as we have used dozens of aliquots and had 
only one issue potentially linked to their production.  Several years ago, we 
injected a group of mice with ad-hSAA1 and had most of the mice collapse, 
appearing very ill in a short period of time (<10 minutes) post injection.  Mice 
were given supportive therapy such as warmed 0.9% saline subcutaneously and 
monitored.  All of the mice recovered after about 2 hours and remained healthy 
for the duration of the study they were participating in.  One possible explanation 
for such a dramatic acute collapse would be LPS contamination in the viral 
aliquot likely from a contaminated tube that the viral aliquot was stored in, 
although a definitive cause of the animals’ distress was never pinpointed.   
 
It is also worth noting that the mice from both the 1D11 group (which failed 
to express human SAA) and the 13C4 groups received ad-hSAA1 from the same 
pooled aliquots of virus.  The 13C4 group did express SAA so the virus was 
obviously sufficiently virulent to infect the mice.  This implies that every step prior 
to injection was done accordingly and the problem with ad-hSAA1 expression in 
the 1D11 group lies elsewhere.   
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In my thesis work and the pilot SAA/1D11 study mentioned above, the 
1D11 antibody was from the same manufacturer, though the lots were different.  
Of note,  we have noticed in the past that manufacturers will change storage 
conditions (such as the inclusion of azide in buffer)  and not communicate them 
well to the end user.  It is highly unlikely that this would result in a problem but 
certainly worth mentioning.  So at this point we have three studies using both ad-
hSAA1 and 1D11 concurrently.  Two of the three studies had elevated SAA 
expression as would be expected.  The third study was designed to investigate 
the requirement of TGF-β in SAA mediated atherosclerosis. In that study ad-
hSAA1 and 1D11 antibody were concurrently injected; however, elevation of 
human SAA was not achieved, thus no conclusion regarding TGF-β’s role in SAA 
mediated atherosclerosis can be made.  These results are certainly unsettling 
and will constitute a major portion of the future directions of this thesis.  
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Chapter 8: Conclusions and future directions 
8.1 Conclusions 
 
The work presented in the thesis is summarized in the model below:   
 
 
Figure 8-1:  Working model  
 
 The data in this thesis definitively characterizes serum amyloid A as a 
proatherogenic cytokine capable of orchestrating vascular wall remodeling.  In 
both apoe-/- and rag1-/- x apoe-/- male mice, increased SAA led to an increase in 
atherosclerosis at three common sites of analysis.  This data is supported by 
previous work by Dong et al who demonstrated for the first time that chronic 
overexpression of SAA by lentiviral transfection accelerated the progression of 
atherosclerosis (85).  Their conclusions were based on changes to the vascular 
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endothelium known to contribute to atherosclerosis such as increased VCAM and 
ICAM, leading to increased monocyte adhesion and translocation into the 
developing lesion.  Here we expanded upon their findings by demonstrating that 
chronically elevated SAA, via adenoviral infection, is atherogenic via the 
upregulation of vascular biglycan leading to increased lipid retention.  Both our 
study and Dong et al clearly implicate SAA as a proatherogenic molecule; 
however, timing of our observed effects differed greatly from that presented in 
Dong’s work.  We demonstrated that SAA was acting early to remodel the vessel 
wall such that proatherogenic lipoproteins would be retained leading to the 
inflammatory infiltration observed by Dong.  Taken together these data indicate 
that SAA may be mediating the development of atherosclerosis through multiple 
mechanisms at multiple distinct developmental timepoints in the disease 
progression.  Right now there are literally hundreds of millions of people currently 
living with diseases that include chronically elevated SAA as a hallmark feature.  
These diseases, such as diabetes and obesity confer greater risk of developing 
cardiovascular disease compared to healthy age matched individuals, though 
that risk remains largely unexplained.  Our data demonstrated that chronically 
elevated SAA is pro-atherogenic could certainly provide an explanation for their 
increased CVD risk and warrants further investigation.   
 
 In our preliminary studies we observed increased vascular biglycan 
content 28 days after a single transient increase in SAA.  Biglycan, stimulated by 
SAA has increased GAG chain length and affinity for apolipoprotein B containing 
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lipoproteins.  As Nakashima demonstrated, lipid retention following increased 
matrix deposition precedes inflammatory infiltration into the developing lesion 
(15).   Interesting was the revelation that even a single transient elevation of SAA 
could lead to sustained, stable remodeling of the vasculature such that biglycan 
levels were still elevated 16 weeks after the SAA exposure.  Furthermore, mice 
with only a brief exposure to SAA and subsequent sustained increase in biglycan 
displayed increased atherosclerosis compared to mice with no change in SAA.   
 
In both sustained and briefly elevated SAA studies, increased SAA did not 
alter lipids or lipoprotein distribution, nor did body weight or other anthropometric 
parameters differ.   
 
To further characterize the importance of biglycan in early lesion 
development, we developed the biglycan transgenic mouse and crossed it onto 
the ldlr-/- background.  This model provided a platform to investigate increased 
biglycan independent of the potential confounding effects of elevated SAA.  
Vascular biglycan content was increased in both male and female transgenic 
mice.  These mice exhibited a strong correlation between vascular biglycan 
content and aortic sinus atherosclerosis and also a striking co-localization of 
aortic sinus biglycan and apolipoprotein B containing lipoproteins.   
 
Furthermore, in support of our hypothesis that biglycan is proatherogenic, 
biglycan transgenic mice had increased atherosclerosis within the aortic root and 
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on the aortic intimal surface compared to their wildtype controls.  The increased 
atherosclerosis was independent of other risk factors such as altered cholesterol 
or lipoprotein distribution.   
 
Interestingly our data also revealed that biglycan, clearly pro-atherogenic 
when present, is not absolutely required for the development of atherosclerosis.  
bgn-/- mice injected with ad-hSAA1 actually had increased atherosclerosis 
compared to bgn-/-  mice injected with ad-Null or wildtype mice injected with either 
ad-hSAA1 or ad-Null.   Superficially this data appears to contradict our working 
hypothesis that biglycan is an important molecule in the development of 
atherosclerosis; however, the absence of biglycan does not negate the important 
pathological role it is playing in atherosclerosis when present.  As such, we have 
recapitulated this finding in two other models of biglycan deficient 
atherosclerosis.  In both a biglycan deficient model of AngII-stimulated 
atherosclerosis (53) and a biglycan deficient model of diabetes (in preparation), 
the lack of biglycan resulted in either no difference or increased atherosclerosis 
compared to biglycan wildtype controls, respectfully.  The data presented in this 
thesis regarding the absence of biglycan appears to support those findings; 
however, there are caveats attached to the bgn-/- data (as discussed in chapter 6) 
 
Our studies also demonstrated that apoe-/- VSMC’s treated with murine 
SAA and subsequently incubated with alexa-fluor labeled LDL had increased 
LDL binding compared to control cells.  The increased LDL binding was 
ameliorated with cells were concurrently treated with murine SAA and TGF-β 
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inhibitory antibody 1D11; implicating TGF-β as an intermediate in SAA stimulated 
lipoprotein retention by vascular smooth muscle cell secreted matrix.  
 
8.2 Future directions 
 
 Repeat the TGF-β inhibition study, Chapter 7 8.2.1
 
  Our model of SAA mediated increased biglycan leading to increased 
vascular lipid retention and increased atherosclerosis remains incomplete.  
Previous data from our lab established that SAA acted through TGF-β to 
increase biglycan expression as TGF-β inhibition resulted in decreased vascular 
biglycan.  A thoughtful experiment to clearly establish the role of TGF-β in SAA 
mediated biglycan expression was performed.  However, post experimental 
analysis of human SAA revealed that the group concurrently receiving ad-hSAA1 
and the TGF-β inhibitory antibody 1D11 did not express human SAA.  A thorough 
discussion of this experiment can be found in Chapter 7 (Discussion, page 95).  
This data represents the biggest gap in knowledge within this thesis and also 
represents the first step in moving forward. To further assess our proposed 
mechanism we need to understand TGF-β’s role in SAA mediated 
atherosclerosis. Therefore the experiment presented in chapter 7 needs to be 
repeated.  This data is necessary prior to addressing any additional future 
directions with  this project.   
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 Cross the biglycan transgenic mouse to the apoe-/- 8.2.2
mouse  
 
Beyond addressing the TGF-β inhibition experiments, the fact that the 
biglycan transgenic mice presented in Chapter 5 were crossed to the ldlr-/- is the 
next issue to resolve.  The biglycan transgenic mouse needs to be crossed to the 
apoe-/- mouse, thus a direct comparison of non-stimulated, increased vascular 
biglycan can be more thoroughly related to the other experiments presented 
here, were the mice were all apoe deficient.   The current biglycan transgenic 
model, crossed to an ldlr -/- mouse, was developed for investigating biglycan 
overexpression as a means of furthering research already begun into the role of 
angiotensin II increased biglycan expression in the vasculature.  It proved to be a 
very useful tool for eliminating the confounding effects of angiotensin II which are 
many when discussing atherosclerosis development (53).   Although apoe-/-  and 
ldlr -/- mice are considered the gold standards for modeling atherosclerosis and 
are quite similar, there are differences worth noting.  apoe-/- mice will 
spontaneously develop lesions independent of dietary modification, but another 
pro-atherogenic insult such as diet is required for atherosclerosis development in 
ldlr -/- mice.   apoe-/- mice tend to carry the bulk of their cholesterol on remnant 
particles whereas ldlr -/- mice utilize LDL for cholesterol transport.   However, the 
most crucial attribute to apoe-/-   lesion development is that it closely mimics the 
progression and severity of human lesions; thus, is more representative of the 
disease we are ultimately investigating (119).  Given that apoe-/- mice carry the 
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bulk of their lipid on chylomicrons and VLDL remnants which are predominantly 
apoB48 particles, it is plausible that biglycan mediated lipid retention is not the 
only mechanism by which lipoproteins are retained in an apoe-/- mouse.  Heparin 
and lipoprotein lipase have both been implicated in lipid retention as well (120).  
As it stands now, biglycan transgenic mice on an ldlr -/-  background have more 
atherosclerosis independent of other confounding factors, we will need to 
conduct experiments in the biglycan transgenic apoe-/- mouse to see if those data 
are replicated.  The previously proposed experiments would resolve the issues 
directly related to the thesis work presented.  However, several observations 
made within studies related to this thesis and other work being conducted in our 
lab introduced questions that should also be investigated as part of a bigger 
more comprehensive evaluation of SAA mediated atherosclerosis that was 
beyond the scope of this thesis.   
 
 Determine the role of perlecan in SAA mediated 8.2.3
atherosclerotic lesions 
 
Our hypothesis that biglycan was the predominant lipid retaining molecule 
in the vasculature was brought into question by findings in this thesis and other 
work in our lab.   Within our SAA model, we demonstrated a significant increase 
in atherosclerosis in mice lacking biglycan. In a model of diabetic nephropathy 
and one investigating angiotensin II induced atherosclerosis, both using a 
biglycan deficient mouse and wildtype controls, the amount of atherosclerosis 
was either not different (angiotensin II) or strikingly higher (diabetic model) when 
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biglycan was absent.  In the model of diabetic nephropathy, male bgn-/- x ldlr-/- 
and bgn wildtype mice were injected with streptozotocin, to induce a type 1 
diabetic phenotype, or citrate buffer and maintained on a 0.12% cholesterol diet 
for 26 weeks.  Atherosclerosis was analyzed in two sites, the aortic intimal 
surface and the aortic sinus.  In both sites, the extent of atherosclerosis was 
significantly greater in the diabetic mice lacking biglycan (manuscript in 
preparation).  In the model of angiotensin II induced atherosclerosis, bgn-/- x ldlr-/- 
mice were given angII or saline infusion followed by western diet for 6 weeks.  
Interestingly the lack of biglycan was not atheroprotective as was hypothesized.  
The mice lacking biglycan had the same extent of atherosclerosis in the aortic 
sinus and on the aortic intimal surface as the wildtype angII infused mice (29).  
We had previously demonstrated that infusion of angII via alzet minipump 
increased both biglycan and perlecan expression in mice (34).  The angII 
mediated increase in perlecan was not TGF-β dependent as mice co-treated with 
angII and the TGF-β inhibitory antibody 1D11 only demonstrated reduced 
vascular biglycan content, but no effect on perlecan content (29).  It is therefore 
plausible that biglycan exhibits some as yet described regulatory role over 
perlecan expression.  Thus, within our SAA model of atherosclerosis, findings 
that mice lacking biglycan had increased atherosclerosis could be explained by 
increased perlecan content.  To address this question, vascular tissues should 
be probed for perlecan using multiple approaches including western blot and 
immunohistochemistry to determine what is happening to perlecan levels in the 
presence or absence of biglycan.  However, there is a significant caveat that 
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must be considered when addressing perlecan in atherosclerosis.  It has also 
been shown that, at least in murine lesions, apolipoprotein B containing 
lipoproteins colocalize with perlecan (37).  However, even though perlecan is the 
primary heparan sulfate proteoglycan in human arteries its expression is 
markedly decreased within human atherosclerotic lesions (117, 121) .    
 
 
 Determine what role locally synthesized vs. systemic SAA is playing 8.2.4
in the development of atherosclerosis.   
 
Our study focused on SAA1, one of two isoforms of SAA closely 
associated with the acute phase response.  SAA1 is mainly produced in the liver 
then secreted into circulation after hepatic stimulation via inflammatory molecules 
(60).  SAA’s association with inflammation and its utility as an inflammatory 
marker for diseases such as atherosclerosis are based on measuring alterations 
in SAA levels in plasma (122).  We and others have demonstrated that, when 
elevated even briefly, the acute isoforms of SAA are proatherogenic (Chapters 3 
& 4, (85).   However, the necessity of acute phase isoforms of SAA in the 
development of atherosclerosis was recently questioned.  Male and female  
apoe-/- mice were compared to apoe-/- mice also deficient in both SAA 1.1 and 
SAA 2.2.  All mice were fed a chow diet for 50 weeks.  Atherosclerosis was 
analyzed on the arch, thoracic and abdominal intimal surface and no differences 
were observed between mice regardless of the presence or absence of SAA. 
The experiment was repeated, replacing the normal rodent chow previously used 
with western diet for 12 weeks.  The results were the same; there were no 
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observed differences in atherosclerosis between groups (123).  These data 
indicate that acute SAA may be important for the progression of early 
atherosclerosis; however, it may not be required.    
 
SAA has been found in atherosclerotic lesions of both apoe-/- and  ldlr-/-
 mice co-localized with apolipoprotein-AI and apolipoprotein B containing 
lipoproteins (83).  We have also demonstrated SAA’s presence in lesions of 
apoe-/- mice (data not shown); however, the specific isoform of SAA within the 
lesion has never been determined.  Interestingly, many cell types found in 
atherosclerotic lesions have been shown to express SAA including 
macrophages, endothelial cells, vascular smooth muscle cells and adipocytes 
(124).  Thus, further investigation of the lesional content and specific isoforms of 
locally synthesized SAA within atherosclerotic lesions would be beneficial.  I 
propose utilizing laser capture microscopy to investigate lesions of apoe-/- mice 
compared to lesions of apoe-/- mice also deficient in SAA 1.1 and SAA 2.1 to 
determine if the expression of SAA3, the extrahepatic, acute isoform of SAA in 
mice is altered between the different groups.  The SAA3 isoform does not 
contribute to circulating SAA so its expression levels cannot simply be accessed 
by plasma analysis using ELISAs.  If SAA3’s expression levels were higher in the 
SAA 1.1 and SAA 2.1 deficient mice it would imply that the acute phase SAAs of 
hepatic origin may exhibit some down regulation of SAA3 that is not observed 
when SAA 1.1 and 2.1 are absent.  This could also imply that SAA3 is 
conditionally proatherogenic in the absence of SAA 1.1 and 2.1  
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